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     “A Rare Disorder, Yes; an Unimportant One, Never”
Angelo M. DiGeorge, 1975
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ABSTRACT
Much of the global cancer research is focused on the most prevalent tumors; yet, less
common tumor types warrant investigation, since “A rare disorder is not necessarily an
unimportant one”. The present work discusses a rare tumor type, the benign adenomas of the
pituitary gland, and presents the advances which, during the course of this thesis work,
contributed to the elucidation of a fraction of their genetic background.
Pituitary adenomas are benign neoplasms of the anterior pituitary lobe, accounting for
approximately 15% of all intracranial tumors. Pituitary adenoma cells hypersecrete the
hormones normally produced by the anterior pituitary tissue, such as growth hormone (GH)
and prolactin (PRL). Despite their non-metastasizing nature, these adenomas can cause
significant morbidity and have to be adequately treated; otherwise, they can compromise
the patient’s quality of life, due to conditions provoked by hormonal hypersecretion, such as
acromegaly in the case of GH-secreting adenomas, or due to compressive effects to
surrounding tissues.
The vast majority of pituitary adenomas arise sporadically, whereas a small subset occur as
component of familial endocrine-related tumor syndromes, such as Multiple Endocrine
Neoplasia type 1 (MEN1) and Carney complex (CNC). MEN1 is caused by germline
mutations in the MEN1 tumor suppressor gene (11q13), whereas the majority of CNC cases
carry germline mutations in the PRKAR1A gene (17q24). Pituitary adenomas are also
encountered in familial settings outside the context of MEN1 and CNC, but unlike in the
latter syndromes, their genetic background until recently remained elusive. Evidence in
previous literature supported the notion that a tumor suppressor gene on 11q13, residing
very close to but still distinct from MEN1, causes genetic susceptibility to pituitary tumors.
The aim of the study was to identify the genetic cause of a low penetrance form of Pituitary
Adenoma Predisposition (PAP) in families from Northern Finland. The present work
describes the methodological approach that led to the identification of aryl hydrocarbon
receptor interacting protein (AIP) as the gene causing PAP. Combining chip-based
technologies (SNP and gene expression arrays) with traditional gene mapping methods and
genealogy data, we showed that germline AIP mutations cause PAP in familial and sporadic
settings. PAP patients were diagnosed with mostly adenomas of the GH/PRL-secreting cell
lineage. In Finland, two AIP mutations accounted for 16% of all patients diagnosed with
GH-secreting adenomas, and for 40% of patients being younger than 35 years of age at
diagnosis. AIP is suggested to act as a tumor suppressor gene, a notion supported by the
nature of the identified mutations (most are truncating) and the biallelic inactivation of AIP
in the tumors studied. AIP has been best characterized as a cytoplasmic interaction partner
of aryl hydrocarbon receptor (AHR), also known as dioxin receptor, but it has other partners
as well. The mechanisms that underlie AIP-mediated pituitary tumorigenesis are to date
largely unknown and warrant further investigation.
Because AIP was identified in the genetically homogeneous Finnish population, it was
relevant to examine its contribution to PAP in other, more heterogeneous, populations.
Analysis of pituitary adenoma patient series of various ethnic origins and differing clinical
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settings revealed germline AIP mutations in all cohorts studied, albeit with low frequencies
(range 0.8-7.4%). Overall, PAP patients were typically diagnosed at a young age (range 8-41
years), mainly with GH-secreting adenomas, without strong family history of endocrine
disease. Because many PAP patients did not display family history of pituitary adenomas,
detection of the condition appeared challenging. AIP immunohistochemistry was tested as a
molecular pre-screening tool on mutation-positive versus mutation-negative tumors, and
proved to be a potentially useful predictor of PAP.
Mutation screening of a large cohort of colorectal, breast, and prostate tumors did not reveal
somatic AIP mutations. These tumors, apart from being the most prevalent among men and
women worldwide, have been associated with acromegaly, particularly colorectal neoplasia.
In this material, AIP did not appear to contribute to the pathogenesis of these common
tumor types and other genes seem likely to play a role in such tumorigenesis.
Finally, the contribution of AIP in pediatric onset pituitary adenomas was examined in a
unique population-based cohort of sporadic pituitary adenoma patients from Italy.
Germline AIP mutations may account for a subset of pediatric onset GH-secreting adenomas
(in this study one of seven GH-secreting adenoma cases or 14.3%), and appear to be
enriched among young (?25 years old) patients.
In summary, this work reveals a novel tumor susceptibility gene, namely AIP, which causes
genetic predisposition to pituitary adenomas, in particular GH-secreting adenomas.
Moreover, it provides molecular tools for identification of individuals predisposed for PAP.
Further elaborate studies addressing the functional role of AIP in normal and tumor cells
will hopefully expand our knowledge on endocrine neoplasia and reveal novel cellular
mechanisms of pituitary tumorigenesis, including potential drug targets.
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REVIEW OF THE LITERATURE
1. The human genome and tumorigenesis
Tumors are lesions caused by the abnormal growth of cells in various tissues. They are
broadly divided into two categories: The benign tumors that remain localized, without
invading adjacent tissues, such as the adenomas, and the malignant tumors (i.e. cancer) that
acquire invasive potential towards adjacent tissues and can spawn metastases elsewhere in
the body. The development of tumors is a complex phenomenon attributed to many causes;
these are regarded as external – including tobacco use, exposure to chemicals and
ionizing/ultraviolet radiation, exposure to infectious microorganisms, dietary habits, alcohol
consumption, or obesity – or internal, including inherited DNA mutations causing genetic
predisposition to tumor development, acquired (i.e. somatic) genomic alterations, or
prolonged exposure to hormones and growth factors.
The vast majority of tumors occur due to mutations that human cells accumulate during
one’s lifetime. The spontaneous mutation rate in mammalian cells from normal tissues is
exceedingly low (<10-8) (Bielas et al., 2006) and accumulation of a considerable number of
mutations is required for transformation from normal cells to neoplastic ones. Some tumor
types (i.e. colorectal and breast cancers) have been found to harbor around 15 mutations
likely to be involved in driving initiation, progression, or maintenance of the tumor (Wood
et al., 2007). These mutations, known as “drivers”, confer a growth advantage on the cell in
which they occur, and are, thus, positively selected. On the other hand, “passenger”
mutations are expected to be biologically neutral, since they do not confer growth advantage
and are not causative of tumorigenesis (Greenman et al., 2007). Apart from the well
recognized genomic alterations that occur in specific tumor types, the genomes of tumor
cells display genomic instability in the form of greatly elevated frequencies of random
mutations. Thus, it was proposed that tumor cells exhibit a mutator phenotype (Loeb, 1991;
Bielas et al., 2006). These altered genotypes constitute a permissive environment for a tumor
cell to acquire novel physiological capabilities, such as: a) self-sufficiency in growth signals,
b) insensitivity to growth-inhibitory signals, c) evasion of apoptosis, d) limitless replicative
potential, e) sustained angiogenesis, f) tissue invasion and metastasis (Hanahan &
Weinberg, 2000) and possibly g) evasion of immune system-mediated elimination
(Weinberg, 2007).
Approximately 380 genes, representing about 1% of all human genes, have been implicated
via mutation in tumorigenesis (Futreal et al., 2004; The Wellcome Trust Sanger Institute,
August 2008 at www.sanger.ac.uk/genetics/CGP/Census). In their vast majority (90%), these
genes are somatically mutated, and only a small subset harbor mutations in the germline
(20%), or both germline and somatic level (10%) (Futreal et al., 2004). The distinct gene
categories implicated in tumorigenesis are the oncogenes, the tumor suppressor genes
(TSGs), and the “caretaker” genes, which are the genes that maintain the genomic stability.
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1.1 Oncogene activation
Oncogenes are the mutated versions of normal genes – called proto-oncogenes – that code
for proteins involved in a variety of key cellular processes, including cell proliferation,
differentiation, and apoptosis. The oncogenic protein products can be distinguished in the
following categories, based on their subcellular localization and functional roles: Growth
factors (e.g. PDGF-?), growth factor receptors (e.g. EGFR), signal transducers (e.g. RAS),
transcription factors (e.g. ETS family), chromatin remodelers (e.g. MLL), and apoptotic
regulators (e.g. BCL2) (Croce et al., 2008).
The activation of proto-oncogenes to oncogenes may be the result of a number of genomic
alterations, such as activating point mutations, gene fusions due to chromosomal
rearrangements, juxtaposition of proto-oncogenes to enhancer elements, or gene copy
number amplifications. Point mutations and translocations usually occur as initiating
events, or during tumor progression, whereas amplification usually occurs during tumor
progression (Croce et al., 2008). These alterations result in either increased expression of the
normal protein, due to constitutive gene activation, or expression of an aberrant protein,
such as chimeric proteins that result from chromosomal translocations (Table 1). The latter
are the most common class of somatic mutations occurring mainly in hematopoietic
malignancies (i.e. leukemias), but also in epithelial neoplasms, such as sarcomas (Delattre et
al., 1994), thyroid carcinoma (Kroll et al., 2000), and prostate cancer (Tomlins et al., 2005).
Because oncogenic activation is manifested even if only one gene copy is altered (in terms of
alterations on the genomic sequence level or the expression level), oncogenes are thought to
act in a dominant manner at the cellular level.
1.2 Loss of tumor suppression
Alfred Knudson proposed a seminal model for tumor development, which, since its
elucidation, expanded to include many tumor types associated with mutational events that
occur in TSGs. Knudson’s so-called “two-hit” hypothesis, based on his epidemiological
studies on pediatric retinoblastoma (Knudson, 1971), suggests that two “hits” (i.e. two
mutational events) must occur in a TSG, one on each allele, in order for an affected cell to
acquire a growth advantage, as a prerequisite for its clonal expansion. Thus, on the somatic
level, TSG inactivation occurs in a recessive manner.
In hereditary tumors, the first mutational event is an inherited germline mutation, which is
present in all cells of an affected individual. The “second hit” occurs as a somatic (i.e.
acquired) mutation in a single cell, resulting in the inactivation of the remaining wild type
gene copy, thus leading to gene inactivation. Because the probability of a single somatic
mutation in one allele is much higher than the probability of acquisition of two hits in both
alleles, people already carrying an inherited mutation of a TSG face higher risk of
developing a tumor than the general population (Kinzler & Vogelstein, 1997).
The “second hit” is most often the loss of the remaining gene copy by a mechanism known
as loss of heterozygosity (LOH). This allelic loss can result from erroneous mitotic
recombination or gene conversion events, but it may also be observed on tumor DNA level
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as a large deletion, encompassing anything between few megabases (Mb) up to whole
chromosomal arms or whole chromosome losses (Weinberg, 2007). It appears that large
genomic deletions are not easily tolerated on genomic DNA level, because they may not be
compatible with life; instead, somatic deletions are far more common in individual cells, and
may occur spontaneously (Tomlinson et al., 2001). Chromosomal losses on the somatic level
may result in the ablation of nearby genes, which may have further implications in tumor
growth and progression. Epigenetic changes, such as promoter hypermethylation, are a
common mechanism of gene silencing, estimated to occur in approximately 50% of TSGs in
sporadic tumors (Jones & Baylin, 2002; Weinberg, 2007). Point mutations and intragenic
deletions are less common; these types of “second hits” may compromise the gene
expression or protein function, depending on the type and location of the mutation (i.e.
promoter region, splice-sites, or coding sequence) (Table 1).
The evolution of tumors requires much more than just two hits, though; no tumors have
been found to occur exclusively due to two hits on a single genomic locus. In reality, tumor
growth and progression is a multistep process, characterized by the stepwise accumulation
of several mutational events, including loss-of-function of TSGs, as well as gain-of-function
of one or more oncogenes (Loeb, 1991; Knudson, 2001). In colorectal cancer, for instance, 25-
50% of tumors have been shown to harbor more that nine (Fearon & Vogelstein, 1990) or
even up to 15 mutations (Wood et al., 2007).
Yet, a number of TSGs involved in tumorigenesis do not follow the “two-hit” model.
Haploinsufficiency, described for a number of TSGs mainly in murine models, has been
proposed to lead to accelerated tumorigenesis, since only one defective gene copy is
sufficient to compromise the corresponding protein’s role in the cell (reviewed in Payne &
Kemp, 2005) (Table 1). An example of such an atypical, haploinsufficient TSG is CDKN1B,
which codes for the cyclin-dependent kinase inhibitor p27Kip1, a cell cycle regulatory protein
that inhibits the G1/S phase transition (Sherr & Roberts, 1999). CDKN1B genomic sequence
and mRNA expression levels have been found unaltered in most human or murine tumors
analysed (Slingerland & Pagano, 2000); yet p27Kip1 protein expression is markedly reduced in
common human epithelial cancers, a fact associated also with poor prognosis (reviewed in
Chu et al., 2008). These data indicate that other mechanisms, possibly on the post-
translational level, compromise the cellular functionality of p27Kip1 (Hengst & Reed, 1996;
reviewed in Chu et al., 2008).
1.3 Loss of genomic stability
The stability genes, also known as “caretakers”, code for proteins that monitor and repair
the genomic alterations that normally occur in the cells. Caretaker genes belong to the
mismatch repair system (MMR), the nucleotide-excision repair system (NER), the base-
excision repair system (BER), and the double-strand break repair system (DSBR)
(Hoeijmakers, 2001; Weinberg, 2007). If mutations occur in these genes and render them
inactive or defective, the genome inevitably accumulates genomic alterations that remain
unrepaired. Thus, stability genes act in a different way than oncogenes or TSGs: Caretakers
do not promote tumorigenesis themselves, but rather through the accumulation of
aberrations in other crucial genes, such as TSGs; contrary, oncogenes and TSGs directly
affect cellular mechanisms leading to neoplasia (Kinzler & Vogelstein, 1997).
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Stability genes have been found mutated in a number of hereditary cancer syndromes, such
as hereditary nonpolyposis colorectal cancer (HNPCC) (MMR genes MLH1, MSH2, MSH6,
PMS2), xeroderma pigmentosum (XP) (NER genes XPA-G), and breast and ovarian cancer
(DSBR genes BRCA1 and BRCA2) (Table 2) (Hoeijmakers, 2001; Weinberg, 2007).
Table 1. Mechanisms of gain- or loss-of-function events in tumor predisposing genes.
Mechanism of activation/inactivation Functional result on transcript/protein level
Oncogenes (Gain-of-function)
Point mutation (missense) Constitutively active protein
Chromosomal translocations or inversions resulting in
fusion genes
Fusion transcripts leading to fusion proteins with
aberrant activity
Chromosomal  translocations or inversions resulting in
juxtaposition to an enhancer element
Overexpression of the normal protein
Gene amplification Overexpression of the normal protein
Promoter hypomethylation Activation of transcription of a silenced proto-
oncogene
TSGs and stability genes (Loss-of-function)
Point mutation (nonsense, missense)
Early nonsense mutation
Late nonsense or missense mutation
Loss of protein
Hypomorphic or dominant-negative protein
Insertions or deletions resulting in frameshift
Premature stop codon
Late stop codon
Elongated transcript
Loss of protein
Hypomorphic or dominant-negative protein
Loss of protein or dominant-negative protein
Small in-frame deletions Loss of functional or interaction domains
Hypomorphic or dominant-negative protein
Large genomic deletions
Whole gene deletion
Partial (exon(s)) deletion
Loss of protein
Loss of protein or dominant-negative protein
LOH Loss of protein
Epigenetic silencing by promoter hypermethylation Transcription silencing
Haploinsufficiency Reduced expression of the normal protein
1.4 Genetic predisposition to tumor development
Inherited tumor susceptibility accounts for a small subset of all neoplasias (5-10%) (Nagy et
al., 2004); yet, the elucidation of a variety of rare familial tumor syndromes has had a great
impact on our understanding of tumor genetics and has confirmed that cancer, in its
essence, is a disease of the genome (Vogelstein & Kinzler, 2004). In addition, it has provided
ground for the study of sporadic tumors as well, and has greatly improved our knowledge
on novel molecular pathways implicated in tumorigenesis (Fearon, 1997).
The majority of inherited tumor susceptibility syndromes are transmitted as autosomal
dominant traits, with varying penetrance (i.e. disease expressivity) observed either between
affected members of the same family or between affected members from different families
with the same predisposing mutations (Marsh & Zori, 2002). Most of these syndromes are
caused by germline mutations in more than 30 TSGs and oncogenes, a fraction of which is
presented in Table 2. The latter category includes only a handful of examples, such as RET,
MET, KIT, CDK4, and ALK as the predisposing genes in Multiple Endocrine Neoplasia type
2 (MEN2) (Mulligan et al., 1993), hereditary papillary renal cell carcinoma (HPRCC)
Genetic Basis of Pituitary Adenoma Predisposition
14
(Schmidt et al., 1997), familial gastrointestinal stromal tumors (GIST) (Nishida et al., 1998),
familial malignant melanoma (FMM) (Zuo et al., 1996), and familial neuroblastoma (Mosse et
al., 2008), respectively. A fairly small number of hereditary tumor predisposition syndromes
are transmitted as autosomal recessive traits (Table 2); these cases are rare and are not
expected to be enriched in the general population, due to the often life-limiting character of
the disease and the hampered potential of the affected individuals to produce offspring.
In highly penetrant conditions, affected individuals manifest the disease phenotype at a
considerably younger age than their sporadic counterparts; this is due to the shorter time
elapse before a “second hit” occurs in a predisposed tissue that already harbors a germline
genetic defect. Other features that typically characterize highly penetrant familial tumor
syndromes include: a) several affected cases in the family with the same rare tumor
phenotype; b) several generations affected; c) bilateral disease, such as bilateral breast
tumors in breast and ovarian cancer (BRCA), or multiple disease sites in one organ, such as
the colonic polyps in polyposis syndromes of the gastrointestinal (GI) tract; d) multiple
primary cancers in a single individual, such as the colorectal and endometrial tumors in
HNPCC patients; e) disease phenotype in the less affected sex, such as the male breast
cancer seen in BRCA2 families; and f) tumors associated with other conditions, such as the
skin pigmentation seen in Carney complex (CNC) patients (Marsh & Zori, 2002; Nagy et al.,
2004). The highly penetrant tumor predisposing alleles are rarely encountered in the general
population, in other words predisposing mutations are rare in sporadic counterparts.
On the contrary, low-penetrance alleles may be more common in the general population,
since the presence of a predisposing allele does not necessarily cause a disease-associated
phenotype, or it may be associated with age-related penetrance and gender-specific risks
(Fearon, 1997; Nagy et al., 2004). Interactions between, yet unidentified, low-penetrance
genes or between genes and environmental factors may account for another 15-20% of all
human cancers (Nagy et al., 2004). For this reason, low-penetrance susceptibility conditions
are more difficult to identify, presumably owing to the lower frequency of clustering of
affected cases in pedigrees. Moreover, low-penetrance tumor syndromes are more
challenging in terms of genetic counseling and management of the mutation carriers.
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Table 2. Highly penetrant hereditary tumor syndromes and the predisposing genes
(adapted from Fearon, 1997; Marsh & Zori, 2002; Nagy et al., 2004; Garber & Offit, 2005).
Clinical syndrome Predisposing gene Gene
function
Tumor spectrum
Autsomal dominant pattern
of inheritance
Carney complex (CNC) PRKAR1A TSG Cardiac and other myxomas, anterior
pituitary tumors, schwannomas
Cowden syndrome (CS) PTEN TSG Breast, thyroid, endometrial, CNS
cancers, GI polyps
Familial adenomatous
polyposis (FAP)
APC TSG Adenomatous colonic polyps, increased
risk of colorectal cancer
Familial malignant
melanoma (FMM)
CDK4
CDKN2A
Oncogene
TSG
Malignant melanoma
Malignant melanoma, pancreatic cancer
Familial neuroblastoma ALK Oncogene Pediatric neuroblastomas
Familial retinoblastoma PRB TSG Pediatric retinoblastoma, osteosarcoma
Familial gastrointestinal
stromal tumors
KIT Oncogene GI stromal tumors
Hereditary breast and
ovarian cancer (BRCA)
BRCA1
BRCA2
TSG
TSG
Breast and ovarian cancer
Breast and prostate cancer
Hereditary leiomyomatosis
and renal cell cancer
(HLRCC)
FH TSG Skin and uterine leiomyomas, renal
carcinoma
Hereditary papillary renal
cell cancer (HPRCC)
MET Oncogene Papillary renal cell carcinoma
Hereditary nonpolyposis
colorectal cancer (HNPCC)
MLH1, MSH2, MSH6,
PMS1, PMS2, MSH3,
TSGs Colorectal, endometrial
adenocarcinoma, gastric, ovarian,
kidney cancer
Juvenile polyposis (JP) SMAD4/DPC4, BMPR1A TSGs Juvenile polyps of the GI tract,
increased risk of colorectal, GI, and
pancreatic cancer
Li-Fraumeni TP53, CHEK2 TSGs Breast cancer, sarcomas, leukaemia,
brain tumors
Multiple endocrine
neoplasia type 1 (MEN1)
MEN1 TSG Parathyroid hyperplasia/adenomas,
enteropancreatic neuroendocrine
tumors, anterior pituitary adenomas
Multiple endocrine
neoplasia type 2 (MEN2)
RET Oncogene Medullary thyroid cancer,
pheochromocytoma, parathyroid
hyperplasia
Neurofibromatosis type 1
(NF1)
NF1 TSG Neurofibromas, brain and skin tumors
Neurofibromatosis type 2
(NF2)
NF2 TSG Neurofibromas, schwannomas, brain,
spinal, and skin tumors
Peutz-Jeghers syndrome
(PJS)
STK11/LKB1 TSG GI tract carcinoma, breast, pancreatic,
ovarian, testicular cancers
von Hippel-Lindau (VHL) VHL TSG Renal cell carcinoma,
hemangioblastomas,
pheochromocytomas
Autosomal recessive
pattern of inheritance
Ataxia-telangiectasia (AT) ATM TSG Lymphoma, leukaemia, breast cancer
Bloom syndrome BLM TSG Solid tumors, leukemia
Fanconi’s anemia FANCA, B, C, D2, E, F, G
BRCA2
TSGs Leukemia, squamous carcinomas,
hepatoma
Xeroderma pigmentosum
(XP)
XPA, B, C, D, E, F, G TSGs Skin cancers (squamous cell carcinoma,
malignant melanoma), leukemia
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1.5 Identification of tumor predisposing genes
Most tumor predisposing genes have been identified by positional cloning, without pre-
existing hypotheses on their biological function. The primary positional clues can be diverse,
including chromosomal rearrangements visible in metaphase spreads of cancer cells, DNA
copy number changes identified by, for instance, comparative genomic hybridisation (CGH)
and fluorescence in situ hybridization (FISH), or clues after genetic linkage analysis (Futreal
et al., 2004; Shih & Wang, 2005).
Powerful linkage analysis on large, multigenerational pedigrees has been a traditional
disease gene identification approach, successfully applied also in the quest for tumor
predisposing genes. Heredity contributes to the etiology of tumor development by a small
fraction; yet, the crucial identification of large families segregating particular tumor
phenotypes revealed an important number of tumor susceptibility genes. Before the era of
the Human Genome Project, one approach for the identification of such genes was
positional cloning. This term describes the approach of cloning a disease predisposing gene
first by identifying its chromosomal location, followed by laborious efforts in identifying
and cloning the gene itself.
The key element in positional cloning is the collection of a sufficient number of families
segregating a particular tumor phenotype, who are then analysed by genome-wide linkage
analysis, using polymorphic DNA microsatellite markers. A genetic locus is established and
a physical map of the region is constructed by utilizing the informativity obtained by key
meiotic recombinations. When searching for TSGs in tumor predisposition syndromes,
tumor LOH analysis can greatly assist the candidate locus fine-mapping effort; LOH is the
most common type of somatic gene inactivation, and tumors arising in the context of the
syndrome frequently exhibit somatic loss of the wild-type allele of markers in the vicinity of
the susceptibility gene. Next, sequencing of the minimal candidate locus aims at identifying
presumably pathogenic mutations harbored in a candidate gene. Alternatively, if the
number of genes in the linked region is very high, the most likely candidates are selected
based on their functional relevance to the disease, an approach designated as “positional
candidate gene” strategy (Collins, 1995). Identification of the MEN2, HPRCC, FMM, and
HNPCC genes are some examples of the success of the approach (reviewed in Collins, 1995;
Fearon, 1997).
With the completion of the Human Genome and HapMap projects (Lander et al., 2001;
Venter et al., 2001; International Human Genome Sequencing Consortium, 2004;
International HapMap Consortium, 2005; 2007), the complete human DNA sequence, and
many of its common genetic variants, such as the single nucleotide polymorphisms (SNPs),
have become known and globally available. The era of modern human genetics offers new
possibilities in identifying novel tumor predisposing genes. Current approaches may still
include positional cloning; yet, nowadays, pure gene cloning has been replaced by
retrieving relevant genomic information from DNA sequence databases by utilizing
bioinformatic tools. Yet, the powerful sequencing platforms and the high-throughput chip-
based molecular methodologies, such as high-density SNP and gene expression microarrays,
have aided in the identification of novel tumor susceptibility genes: TSGs involved in
autosomal dominantly inherited predisposition to conditions associated with tumor
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formation (Horvath et al., 2006), or autosomal recessive tumor syndromes (Vahteristo et al.,
2007), or identification of oncogenes predisposing to autosomal dominant familial cancers
with incomplete penetrance (George et al., 2007; Mosse et al., 2008). Despite the advances in
the methodological and experimental front, one major challenge that remains in tumor gene
identification is the recognition and collection of suitable family materials segregating rare
tumor phenotypes. Genetically homogeneous populations, such as the Finns, or isolated
inbred populations may serve as ideal material towards this end.
The identification of tumor susceptibility genes necessitates subsequent efforts in
establishing the associated tumor risk (i.e. the disease penetrance) in familial settings, as
well as in the general population. Moreover, the elucidation of histologic,
immunohistochemical, and molecular features, which characterize the component tumors,
are essential for the functional and biological validation of a newly identified tumor gene.
These approaches eventually aim at developing effective strategies for surveillance,
prevention, disease management, and even targeted molecular-based intervention (Nagy et
al., 2004; Garber & Offit, 2005).
Unravelling the role of tumor susceptibility genes can be greatly assisted by genetically
engineered animal models by manners impossible to perform in humans. Even though
animal models are not always successful in depicting human phenotypes (Antonarakis &
Beckmann, 2006), they are expected to aid in the elucidation of certain mechanisms
underlying human tumorigenesis. Genetic engineering of mouse Msh6 and Brca2/p53
resulted in the successful recapitulation of human hereditary non-polyposis colorectal
carcinoma and breast ductal carcinoma, respectively (reviewed in Frese & Tuveson, 2007).
However, the disease outcome in model organisms may largely depend on the approaches
used; germline knockout of a mouse TSG might result in a different tumor phenotype than
its conditional (i.e. tissue-specific) biallelic deletion. This was, for instance, the case with the
neurofibromatosis 2 gene, where Nf2 heterozygous mice developed primarily osteosarcomas,
among other malignancies (McClatchey et al., 1998), whereas conditional ablation of Nf2 in
Schwann cells resulted primarily in the development of benign schwannomas, as in human
NF2 patients (Giovannini et al., 2000). Differences in tumor spectrum and incidence may be
attributable to the specific genetic backgrounds of mice strains or may truly reflect species-
specific differencies (Fearon, 1997).
2. The pituitary gland
The pituitary gland, also known as hypophysis, is one of the most important glands of the
mammalian endocrine system. Through its secreted hormones (see 2.1.1 and 2.1.2), it
controls the growth and activity of three other endocrine glands: The thyroid, the adrenals,
and the gonads. The pituitary is not, however, acting independently, but it is under the
continuous control of the nervous system through the hypothalamus. A wide range of
external stimuli – varying from the supply of nutrients, the ambient temperature, or
exercise, to physical or psychological stress – causes secretion of hypothalamic hormones.
As a response to hypothalamic control, the pituitary secretes the hypophyseal hormones,
which maintain crucial homeostatic functions, including metabolism, growth, and
reproduction (Fig. 1). These two glands compose the “hypothalamopituitary axis”
Genetic Basis of Pituitary Adenoma Predisposition
18
(Goodman, 2003). Apart from the hypothalamic inputs, pituitary hormone secretion is also
regulated by the feedback effects of the circulating hormones, as well as the autocrine and
paracrine secretions of the pituitary cells (Fig. 1) (Bilezikjian et al., 2004; Mechenthaler, 2008).
2.1 Morphology and histology
The pituitary gland is situated at the base of the brain, under the optic chiasm, inside a bony
cavity called “sella turcica”. It is connected to the hypothalamus by the pituitary stalk, the
latter consisting of blood vessels and the axons of the hypothalamic neuronal cell bodies that
reach the posterior pituitary gland. The hypophysis is composed of the neurohypophysis (or
posterior lobe) and the adenohypophysis (or anterior lobe); the latter is comprised of distinct
types of differentially distributed, hormone-secreting cells (Brook & Marshall, 2001). These
secretory cells release the hormonal peptides of the secretory storage granules to the blood
vessels by exocytosis (Goodman, 2003).
2.1.1 Posterior lobe
The posterior lobe consists of cells secreting the antidiuretic hormone (ADH) or vasopressin.
ADH exerts its physiological role mainly on the kidneys as a response to increased plasma
osmolality or decreased plasma volume, thus mediating the regulation of water levels in the
body. ADH also acts on arterioles by controlling blood pressure. Posterior lobe cells also
produce oxytocin, the hormone that causes the uterus to undergo contractions during
delivery (Brook & Marshall, 2001).
2.1.2 Anterior lobe
The anterior lobe has three distinct anatomical areas, namely the central wedge and the two
lateral wings, and is composed of six distinct cell types (Heaney & Melmed, 2004). Three
main pathways of cell differentiation have been elucidated in the anterior pituitary:
Differentiation to adrenocorticotrophs, bihormonal gonadotrophs, and cells that mature
either into somatotrophs, mammosomatotrophs, lactotrophs, or thyrotrophs (Al-Shraim &
Asa, 2006).
Approximately 50% of all anterior lobe cells are growth hormone (GH)-secreting cells, also
known as somatotrophs, and occupy the largest part of both lateral wings (Heaney &
Melmed, 2004). GH has a crucial role in controlling body growth and metabolism, by acting
either directly on multiple tissues or indirectly, via the hepatic production of insulin-like
growth factors (IGFs, mainly IGF-I) (Brook & Marshall, 2001) (Table 3).
Prolactin (PRL)-secreting cells, also known as lactotrophs, reside in both lateral wings. In
men and nulliparous women they may account for approximately 10% of the anterior
pituitary cells, whereas in multiparous women the number can be up to three times higher
(Heaney & Melmed, 2004). PRL inhibits the function of the gonads, and stimulates breast
enlargement, and milk production during and after pregnancy (Table 3). GH- and PRL-
secreting cells derive from progenitor mammosomatotrophs, which are bihormonal cells
that can differentiate into either somatotrophs or lactotrophs depending on the needs of
each phase the body is in (i.e. growth, or pregnancy and lactation) (Asa & Ezzat, 2002).
During pregnancy, for instance, many PRL-secreting cells are recruited from the population
of mammosomatotrophs. This phenomenon is called “reverse transdifferentiation”, since the
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normal state is gradually re-established following delivery and lactation (Horvath et al.,
1999).
Adrenocorticotrophin (ACTH)-secreting cells, also known as corticotrophs, are localized in
the central wedge and account for approximately 10-20% of all anterior lobe cells (Heaney &
Melmed, 2004). Apart from ACTH, they secrete endorphins, ?-lipotrophin and other pro-
opiomelanocortin derivatives. ACTH stimulates the secretion of glucocorticoid hormone
(cortisol) from the adrenal gland cortex, while cortisol, in turn, concerts metabolic and anti-
inflammatory effects (Goodman, 2003) (Table 3).
Follicle stimulating hormone (FSH) and luteinizing hormone (LH)-secreting cells, or
gonadotroph cells, account for roughly equal numbers as corticotrophs, but are scattered
throughout the anterior lobe (Heaney & Melmed, 2004). These hormones regulate the sex
steroid hormone production in the gonads, as well as the development and maturation of
the germ cells (Table 3).
Lastly, a small percentage of thyrotroph cells (5%), concentrated at the central wedge,
secrete the thyroid stimulating hormone (TSH) (Heaney & Melmed, 2004). TSH is the
stimulus for thyroid hormone (T3/T4) production from the thyroid gland. Thyroid hormone
mainly controls GH synthesis and secretion, metabolism and thermogenesis, as well as fetal
skeletal maturation, and central nervous system development and maturation (Goodman,
2003) (Table 3).
Table 3. Hypothalamic and adenohypophyseal hormones and their functions (adapted from
Brook & Marshall, 2001; Goodman, 2003; Heaney & Melmed, 2004).
Hypothalamic
Hormones
Function Target Organ
Stimulatory
GHRH Induction of GH secretion Anterior pituitary lobe
CRH Induction of ACTH secretion Anterior pituitary lobe
TRH Induction of TSH secretion Anterior pituitary lobe
GnRH Induction of FSH/LH secretion Anterior pituitary lobe
Inhibitory
Somatostatin Inhibition of GH secretion Anterior pituitary lobe
Dopamine Inhibition of PRL secretion Anterior pituitary lobe
Adenohypophyseal
Hormones
Function Target Organ Homeostatic functions
GH Indirect action through the
induction of hepatic  IGF-I
Direct action on several tissues
Bones and cartilage,
soft tissues, adipose
tissue, organs
? Promotion of body growth
? Control of body mass
? Blood glucose regulation
PRL Mammary gland development
Lactation stimulation
Mammary glands ? Milk production
ACTH Induction of glucocorticoid
hormone (cortisol) secretion
Adrenal glands (cortex) ? Metabolism (gluconeogenesis
in liver, catabolism in adipose
tissue, muscles, bone)
? Blood glucose increase
? Anti-inflammatory effects
TSH Induction of thyroid hormone
(T3/T4) secretion
Thyroid gland ? Metabolism and thermogenesis
? Skeletal growth and maturation
? CNS growth and maturation
FSH / LH Induction of sex steroid
hormone production:
Ovaries: Estradiol, progesterone
Testes: Testosterone
Gonads
(ovaries and testes)
? Germ cell development
        (ovulation and spermatogenesis)
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2.1.3 Regulation of hormone secretion
2.1.3.1 Positive regulation
The positive regulation of the anterior pituitary hormones’ expression and secretion, with
the exception of PRL, is controlled by hypothalamic hormones that reach the corresponding
adenohypophyseal cells through the pituitary stalk and exert their regulatory action via the
recognition of the corresponding receptors (Fig. 1, Table 3). Hypothalamic GH-releasing
hormone (GHRH) induces GH secretion; GH reaches the liver and other tissues, through the
systemic circulation, and mediates IGF-I production, which primarily controls the post-natal
linear and organ growth, after the first 8-10 months of life (Brook & Marshall, 2001).
Hypothalamic corticotropin-releasing hormone (CRH) stimulates ACTH secretion, which in
turn stimulates glycocorticoid secretion from the adrenal glands. TSH is positively regulated
by the hypothalamic thyrotropin-releasing hormone (TRH), which stimulates the thyroid
hormone secretion (T3/T4). Finally, hypothalamic gonadotropin-releasing hormone (GnRH)
induces gonadotrophs to produce FSH and LH, which regulate the production of the sex
steroid hormones (estradiol, progesterone, testosterone) in the ovaries and testes (Table 3).
PRL secretion is mainly mediated by the direct action of estrogens on the prolactin gene
transcription level (Heaney & Melmed, 2004).
Figure 1. Schematic
representation of the
mechanisms regulating
the anterior pituitary
hormone secretion at
the pituitary and the
hypothalamic level.
Positive regulation is
indicated by straight
black arrows, whereas
negative regulation is
shown by curved lines
(The brain and pituitary
images are modified
from the website
www.tiscali.co.uk).
2.1.3.2 Negative regulation
The negative regulation of the pituitary hormones is conferred by hypothalamic hormones,
such as somatostatin in the case of GH, and dopamine in the case of PRL (Table 3). Secretion
of pituitary hormones is subject to a negative feedback by the secreted products from the
target glands: GH (and GHRH) secretion is inhibited by IGF-I, the thyroid hormone, or
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cortisol.  Both ACTH and CRH are under the negative feedback control of the peripheral
glycocorticoid hormones. The negative regulation of TSH (and TRH) is exerted by the
thyroid hormone. FSH/LH (and GnRH) are negatively regulated by the sex steroid
hormones (Fig. 1) (Goodman, 2003; Heaney & Melmed, 2004).
2.2 Benign tumors of the anterior pituitary lobe and pathological features
Pituitary adenomas are benign adenohypophyseal tumors that may arise de novo or  due to
lack of suppression by the hypothalamic hormones (Brook & Marshall, 2001). They account
for approximately 15% of all intracranial tumors (Heaney & Melmed, 2004) and are the third
most common intracranial tumor type after meningiomas and gliomas (Scheithauer et al.,
2006). Although classified as benign, many of these lesions are locally invasive and can
cause major effects on a patient’s quality of life, due to aberrant hormone secretion, as well
as compressive effects on nearby tissues or the healthy pituitary (hypopituitarism). Irregular
hormone hypersecretion can lead to a number of well recognised clinical conditions, such as
acromegaly or Cushing’s disease (see section 2.2.3 below).
2.2.1 Incidence and prevalence
Pituitary adenomas occur at an approximately equal incidence in both sexes (Asa & Ezzat,
2002). Their annual incidence is estimated at 19-28 new cases per million people (Davis et al.,
2001; Soares & Frohman, 2004). However, their small size, and their insidious, often
asymptomatic, nature pose a challenge in accurate prevalence estimation (Monson, 2000;
Ezzat et al., 2004). Observations from autopsy series, as well as imaging studies in healthy
individuals, incidentally revealed pituitary lesions (usually microadenomas) in 5-20% of the
examined cases (Burrow et al., 1981; Molitch & Russell, 1990; Hall et al., 1994). In a thorough
meta-analysis of post-mortem and radiological studies, Ezzat et al. (2004) estimated an
overall prevalence of unsuspected pituitary adenomas of 16.7%. The prevalence of clinically
relevant pituitary adenomas is not as high, but it is higher than previously thought, as
observed in a cross-sectional study in Belgium (1/1000 population) (Daly et al., 2006a). A
subsequent study undertaken by 18 centers on three continents has confirmed the high
prevalence of clinically-relevant pituitary adenomas, identified among >700,000 individuals
(average 0.75/1000 population) (Daly et al., 2007a).
2.2.2 Tumor characteristics and classification
Pituitary adenomas are believed to develop by monoclonal expansion of a single neoplastic
cell, due to an acquired intrinsic primary cell defect (genetic or epigenetic) that confers
growth advantage (Asa & Ezzat, 2002). X-chromosome inactivation studies on pituitary
tumors from female patients confirmed monoclonality in all types of adenomas (Herman et
al., 1990; Alexander et al., 1990; Schulte et al., 1991; Gicquel et al., 1992).
Pituitary tumors are most often benign and can grow both slowly and expansively. Enclosed
adenomas have a clear delineation to the rest of pituitary tissue and the sinuses; yet, if the
tumor increases in size, it may invade surrounding structures. Although defined as benign,
nearly 50% of pituitary adenomas invade surrounding tissues, but invasiveness rate differs
between various pituitary adenoma types (Brook & Marshall, 2001; Saeger et al., 2007). Very
rarely do pituitary adenomas become metastatic, and are then referred to as pituitary
carcinomas (see section 2.4).
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Pituitary adenomas are generally classified as “functioning”, when the corresponding
hormones are oversecreted and, thus, cause clinical manifestations of the disease, and “non-
functioning”, when there is no hormone hypersecretion and no aberrant blood hormone
levels observed. The main proportion of non-functioning adenomas produces, however,
enough hormones to be detected by immunohistochemical staining. According to their size,
they can be macroadenomas (i.e. tumors greater than 10 mm in diameter), or
microadenomas (i.e. tumors less than 10 mm in diameter) (DeLellis et al., 2004). The
complete classification of pituitary adenomas is based on functional, imaging/surgical,
histopathological, immunohistochemical, and ultrastructural features (Kovacs et al., 1996).
2.2.3 Clinical features
The clinical manifestations of pituitary adenomas could be briefly divided into three
categories: a) signs and symptoms due to excessive hormone secretion (i.e.
acromegaly/gigantism in patients with GH-secreting adenomas, or galactorrhea and/or
reproductive dysfunction in PRL-secreting adenoma patients), b) signs and symptoms due
to mechanical effects of an expanding tumor mass – ranging from headaches and
diminished visual acuity to severe visual disturbances, due to the compression of the optic
chiasm – and c) impairment of the normal pituitary function in the case of large adenomas
causing partial or panhypopituitarism due to compression (Arafah & Nasrallah, 2001). The
major characteristics and clinical manifestations of each pituitary adenoma type are detailed
below and summarized in Table 4.
2.2.3.1 Prolactinomas
PRL-secreting adenomas, also known as prolactinomas, account for the majority of pituitary
tumors (40-45%) (Table 4) (Arafah & Nasrallah, 2001). Their estimated incidence is 6-10 new
cases per million per year and a prevalence of about 60-100 cases per million (Davis et al.,
2001; Ciccarelli et al., 2005). They are reported to occur much more frequently in women
than in men, in particular between the second and third decades of life (Mindermann &
Wilson, 1994), presumably because of the belated recognition of symptoms in men. Elevated
serum PRL concentrations are diagnostic of prolactinomas. Hyperprolactinemia in
premenopausal women causes oligomenorrhea or amenorrhea, in addition to galactorrhea,
because of decreased estogen levels. Due to the early manifestations in young adult women,
tumors are diagnosed as microadenomas. The main presenting symptom in men is sexual
impotence and diminished libido, due to the decrease in testosterone levels, and by the time
of diagnosis tumors are usually macroadenomas (DeLellis et al., 2004; Ciccarelli et al., 2005).
In both sexes fertility is compromised. Other symptoms include headaches and visual
disturbances, as well as variable degrees of hypopituitarism, all manifested in the presence
of macroadenomas (Arafah & Nasrallah, 2001).
2.2.3.2 Somatotropinomas
GH-secreting adenomas, also known as somatotropinomas, account for approximately 20%
of all pituitary tumors (Table 4). These tumors hypersecrete GH, whereas in about a quarter
of them GH hypersecretion is synchronous to PRL hypersecretion. This event may be either
due to the co-presence of somatotroph and lactotroph cells in the tumor (‘dimorphous’), or
due to a mammosomatotroph adenoma (‘monomorphous’), with the same cells secreting
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both GH and PRL. GH hypersecretion leads to acromegaly or gigantism, depending on the
age of occurrence of a GH-secreting adenoma.
Table 4. Classification of pituitary adenomas (adapted from Arafah and Nasrallah, 2001;
Jaffe, 2006)
Adenoma type Prevalence Principal hormone
immunoreactivity
Clinical manifestations
PRL-secreting
(prolactinomas)
40-45% PRL Signs of hyperprolactinemia
GH-secreting
(somatotropinomas)
20% GH ± PRL Acromegaly/Gigantism
ACTH-secreting
(adrenocorticotropinomas)
10-20% ACTH Hypercortisolism
Cushing’s disease
Non-functioning
 (gonadotropinomas)
15% FSH, LH, ?SU, ?SU Compression effects
Non-functioning
(null-cell adenomas)
5-10% None Compression effects
TSH-secreting
(thyrotropinomas)
1-2% TSH Mild hyperthyroidism
Compression effects
FSH/LH-secreting
(gonadotropinomas)
Rare FSH, LH, ?SU, ?SU Ovarian hyperstimulation in women,
gonadal hyperplasia and elevated
testosterone levels in men
Compression effects
Acromegaly
The medical term “acromegaly” originates from the Greek words ‘akro’, which means
‘extreme’ or ‘extremities’, and ‘megas’, which means ‘large’, indicating the enlargement of
the extremities. However, in reality, a large number of organs and tissues are affected. More
than 98% of the acromegaly cases are attributed to GH oversecretion due to a somatotroph
adenoma (Melmed, 1990), whereas the rest are the result of rare excessive hypothalamic or
ectopic GHRH secretion, or even more rare ectopic GH secretion, from a neuroendocrine
tumor (Melmed, 2006). The incidence is estimated to be three to four new cases per million
per year, and the prevalence is about 40-60 cases per million people (Alexander et al., 1980;
Bengtsson et al., 1988; Kauppinen-Makelin et al., 2005). Due to the insidious nature of the
disease, it may take years (~4-10 years) before a definitive diagnosis of acromegaly is made,
usually during the forth or fifth decade of life (Chanson & Salenave, 2008). Prolonged bodily
exposure to increased levels of GH and IGF-I results in increased morbidity in acromegaly.
Table 5 summarizes some of the most prominent clinical features observed in patients with
acromegaly. If left untreated, acromegaly may lead to increased mortality, due to more
severe complications (i.e. cardiovascular, cerebrovascular disease, and diabetes) (reviewed
in Colao et al., 2004 and Erfurth & Hagmar, 2005). The current overall mortality for
acromegaly patients in whom treatment targets are reached, is not estimated to be very
different from that of the general age- and gender-matched population; however, patients
reaching suboptimal post-treatment serum GH levels, and possibly patients having received
irradiation, face an increased mortality risk (Orme et al., 1998; Ayuk et al., 2004; Holdaway et
al., 2004; Kauppinen-Makelin et al., 2005; reviewed in Ayuk & Sheppard, 2008).
Early studies supported that malignancies, such as colorectal, breast, and prostate cancer,
may arise at a higher risk in the context of acromegaly (Nabarro, 1987; Colao et al., 1998;
Jenkins, 2004; reviewed in Colao et al., 2004). Acromegaly patients have increased risk for
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developing premalignant adenomatous colonic polyps and colorectal cancer (Ezzat et al.,
1991; Renehan et al., 2000; Jenkins & Besser, 2001; Kurimoto et al., 2008). A possible
explanation for this might be the trophic (mitogenic, antiapoptotic) effects of excessive IGF-I
on the colonic epithelium, but theoretically on other epithelia, such as the breast and
prostate as well (Jenkins & Besser, 2001). The exact magnitude of the neoplasia risk remains
the subject of much debate, since other epidemiological studies do not support an increased
incidence of de novo malignancy  in  acromegaly  (Orme et al., 1998; Renehan et al., 2000;
reviewed in Melmed, 2001). Lastly, thyroid disorders, including goitre and benign or
malignant tumors, have been detected in several series of acromegaly patients (Gasperi et al.,
2002; Tita et al., 2005; Kurimoto et al., 2008).
Table 5. Clinical features and complications of acromegaly (adapted from: Melmed, 2006;
Chanson & Salenave, 2008; Orphanet, 2008 at www.orpha.net).
Signs and symptoms
1. Enlarged upper and lower extremities (enlarged toes, fingers)
2. Coarsening of facial features (brows, ears, nose, lips)
3. Hyperhydrosis (excessive sweating)
4. Tall stature / Gigantism
5. Fatigue and myopathy (muscle weakness)
6. Goitre (thyroid hyperplasia)
7. Visceromegaly (enlarged salivary glands, heart, liver, spleen, kidneys, prostate)
8. Macroglossia, soft tissue swelling
9. Jaw malocclusion, tooth gaps, prognathism
10. Headaches and visual disturbances
11. Severe snoring, sleep disturbancies
12. Arthralgia (joint pain) and arthritis (limited joint mobility)
13. Carpal tunnel syndrome (wrist neuropathy)
14. Thick, coarse, oily skin and skin tags (skin tissue outgrowths)
15. Menstrual irregularities in women (amenorrhea, galactorrhea)
16. Sexual impotence in men
Complications
1. Hypertension
2. Diabetes mellitus
3. Sleep apnea (due to obstruction of the upper airway)
4. Colorectal polyposis and increased risk for colorectal cancer
5. Cerebrovascular disease
6. Congestive heart failure
Gigantism
Approximately 10% of adult patients with acromegaly exhibit tall stature; however, when a
GH-secreting adenoma develops during childhood or adolescence, before the closure of the
epiphyseal plates of the long bones, it results in accelerated linear growth, a condition called
“gigantism” (Eugster & Pescovitz, 1999). The diagnosis is fairly straightforward, compared
to acromegaly patients who may remain undiagnosed for many years. The majority of
giants eventually develop acromegalic features, but the number of affected cases is not
sufficient to draw any precise figures regarding the prevalence of other signs and symptoms
in children with gigantism (Eugster & Pescovitz, 1999).
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2.2.3.3 Adrenocorticotropinomas
The ACTH-secreting adenomas, also known as adrenocorticotropinomas, account for
approximately 10-20% of all pituitary tumors (Table 4). These adenomas are typically
microadenomas and occur more frequently in women than men (Mindermann & Wilson,
1994). ACTH hypersecretion causes excessive corticosteroid (cortisol) secretion from the
adrenal gland cortex. Cushing’s disease is the condition in which patients exhibit
hypercortisolism almost exclusively due to the presence of an adrenocorticotropinoma, and
very rarely due to ectopic ACTH or CRH secretion. Among the typical signs and symptoms
of hypercortisolism in Cushing’s disease are: Central obesity, easy bruisability,
hyperpigmentation, myopathy, striae, hypertension, hirsutism, menstrual irregularities,
mood changes, osteoporosis, poor wound healing, and hyperglycemia, due to insulin
resistance (Arafah & Nasrallah, 2001).
2.2.3.4 Thyrotropinomas and gonadotropinomas
TSH-secreting adenomas, or thyrotropinomas, are very rare among all pituitary adenomas
(1-2%) (Table 4), and their clinical manifestations may be mistaken for primary thyroid
dysfunction, as the TSH hypersecretion typically results in clinically mild hyperthyroidism.
Thyrotropinomas may grow to macroadenomas (DeLellis et al., 2004). Symptoms are
primarily caused by the hormonal hypersecretion (i.e. mild hyperthyroidism), but also due
to tumor size (i.e. hypopituitarism, headaches, visual field impairment) (Arafah &
Nasrallah, 2001).
Functioning gonadotrophic tumors, or gonadotropinomas, producing FSH and/or LH, or
their respective alpha and beta subunits (?SU or ?SU) are really rare. Symptoms caused by
excessive FSH/LH secretion include ovarian hyperstimulation in women, and gonadal
hyperplasia and elevated serum testosterone levels in men (Arafah & Nasrallah, 2001).
2.2.3.5 Clinically non-functioning pituitary adenomas (NFPA)
Roughly one third of all pituitary adenomas are endocrinologically silent; they produce
hormones that can be detected by immunostaining, but do not cause elevation of the blood
hormone levels, and, thus, no manifestations typical of a hormone oversecretion syndrome
(Heaney & Melmed, 2004). NFPAs may grow insidiously for years and by the time of
diagnosis they are large (>10 mm); thus, their clinical presentation is related to the
mechanical effects of an expanding macroadenoma (hypopituitarism, headaches, visual
defects) (Jaffe, 2006). A subset of NFPAs, accounting for approximately 10-15% of all
pituitary adenomas, produce the gonadotrophic hormones FSH and/or LH, or their
respective alpha and beta subunits (?SU and ?SU). The true NFPAs (i.e. no
immmunoreactive hormone found by immunostaining) are less common (5-10%) and are
referred to as “null-cell” adenomas (Table 4) (Arafah & Nasrallah, 2001).
2.3 Pediatric pituitary adenomas
Pituitary adenomas occur rarely in childhood and adolescence. According to several series,
approximately 2-6% of all surgically treated pituitary adenomas occur in young patients
(Haddad et al., 1991; Partington et al., 1994; Dyer et al., 1994; Mindermann & Wilson, 1995),
whereas approximately 3% of all diagnosed intracranial tumors in childhood are pituitary
adenomas (Keil & Stratakis, 2008). PRL-secreting adenomas are the most common type
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among pubertal and post-pubertal patients (Mindermann & Wilson, 1995), and represent
approximately 50% of pediatric pituitary tumors in several series (Partington et al., 1994;
Kane et al., 1994; Mindermann & Wilson, 1995; Artese et al., 1998; reviewed in Kunwar &
Wilson, 1999). ACTH-secreting adenomas are the second most common adenomas and the
most frequently encountered in early childhood, even though they can occur at all pediatric
ages (Mindermann & Wilson, 1995). The higher frequency of ACTH-secreting adenomas (29-
50%) than GH-secreting adenomas (5-15%) in pediatric patients contrasts observations in
adults (Partington et al., 1994; Dyer et al., 1994; Kane et al., 1994; Mindermann & Wilson,
1995; Colao et al., 2007). NFPAs are rare in children and adolescents (3-6%), despite
representing roughly one third of all pituitary adenomas diagnosed in adults (Partington et
al., 1994; Dyer et al., 1994; Mindermann & Wilson, 1995; Abe et al., 1998). Pediatric TSH- or
FSH/LH-secreting adenomas are extremely rare (Kunwar & Wilson, 1999).
The early onset of pituitary adenomas suggests that tumorigenesis in children and
adolescents may in part be explained by genetic factors, as observed in pediatric onset
pituitary adenomas occurring in the context of Multiple Endocrine Neoplasia type 1 (MEN1)
and CNC (O’Brien et al., 1996; Stratakis et al., 2000; Brandi et al., 2001; Stratakis et al., 2001;
Keil & Stratakis, 2008).
2.4 Carcinomas of the anterior pituitary lobe
Occasionally, invasive pituitary tumors can become aggressive and metastasize to distant
locations in the central nervous system, or systemically reach lymph nodes and other sites
throughout the body, including the liver, lungs, and bones (DeLellis et al., 2004; Scheithauer
et al., 2006). These tumors are referred to as pituitary carcinomas and are characterized as
such only after metastases are identified (Saeger et al., 2007). These carcinomas are extremely
rare, with about 140 cases reported in the literature thus far (Kaltsas et al., 2005; Manahan et
al., 2007). Their incidence has been suggested to be 0.2% of symptomatic pituitary tumors
(Pernicone et al., 1997), with almost equal frequency in both sexes (DeLellis et al., 2004;
Kaltsas et al., 2005). Most are ACTH- or PRL-secreting tumors; GH-, TSH-secreting or
NFPAs rarely develop into carcinomas (Saeger et al., 2007). The time interval between initial
adenoma diagnosis and carcinoma development may vary greatly, depending on the tumor
subtype, with a mean of seven years (Pernicone et al., 1997; Sidibe, 2007). The prognosis is
poor, with a mean survival rate of less than four years (Pernicone et al., 1997; Kaltsas et al.,
2005). The initial clinical, biochemical and histopathological characteristics are of minimal
utility in distinguishing benign adenomas from those that will develop into carcinomas
(Kaltsas et al., 2005; Kars et al., 2006).
3. Genetic features of pituitary tumorigenesis
The pathogenesis of pituitary adenomas has attracted great interest and controversy. It is
established that pituitary adenomas develop by monoclonal expansion of a single cell that
has acquired intrinsic primary genetic (i.e. activation of oncogenes or inactivation of TSGs)
or epigenetic (i.e. methylation) defects that confer a growth advantage. This section shortly
reviews only a handful of possible etiologic genetic features of sporadic pituitary tumor
development. Yet, despite the broad genetic background underlying pituitary
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tumorigenesis, genetic abnormalities are encountered not only as somatic events in sporadic
pituitary tumors, but also in the context of inherited pituitary tumor susceptibility. A more
extensive review is presented later in this chapter, regarding the genetic background of
pituitary adenomas occurring in the context of familial endocrine-related tumor syndromes.
3.1 Sporadic pituitary adenomas
3.1.1 GNAS / gsp oncogene
GNAS (20q13) is a ubiquitously expressed gene that codes for the stimulatory guanosine
triphosphate (GTP)-binding protein Gs?.  Gs? activates adenylyl cyclase, which in turn
increases the cyclic adenosine monophosphate (cAMP) cellular levels; cAMP is a secondary
signal transduction messenger that mediates a signalling cascade through the activation of
protein kinases in many cell types, including pituitary cells. Vallar et al. (1987) found that
two “hot spots” (codons 201 and 227) of GNAS – or gsp oncogene – were frequently mutated
in sporadic GH-secreting adenomas; these mutations caused constitutive activation of Gs?,
resulting in high adenylyl cyclase activity and increased cAMP levels (Vallar et al., 1987). It
is now established that approximately 40% of GH-secreting adenomas harbor somatic
mutations in GNAS (Lyons et al., 1990). Interestingly, Hayward et al. (2001) found that,
contrasted to biallelic Gsa expression in all human tissues, the Gsa expression in the pituitary
is monoallelic – subject to imprinting – and is derived from the maternal allele. Activating
mutations, occuring almost exclusively on the maternal allele, partly explain the underlying
background of somatotroph tumorigenesis (Hayward et al., 2001). Subsequent studies failed
to consistently replicate the finding of GNAS mutations in other types of pituitary adenomas
(reviewed in Lania et al., 2003); data concerning mutations in other G proteins, such as the
stimulatory G?q and G?11, or the ?-subunit of GIP2 – a protein coupled to the inhibitory
Gi?? – were also discordant (Lyons et al., 1990; Petersenn et al., 2000). Gsp activating
mutations in GH-secreting adenomas remain the only unequivocally identified pathogenic
mutations thus far. However, the lack of clinical differences between patients with and
without GNAS mutations is intriguing, suggesting the existence of additional pathogenic
mechanisms (Spada et al., 1990; Adams et al., 1993).
A postzygotic gain-of-function mutation in the GNAS gene is the genetic defect in McCune-
Albright syndrome (MAS) (MIM 174800) (Weinstein et al., 1991; Schwindinger et al., 1992).
MAS is a congenital syndrome characterized by polyostotic fibrous dysplasia, multiple café-
au-lait spots, precocious puberty, and often endocrinopathies, including hyperthyroidism
and GH and PRL excess (Albright et al., 1937; Dumitrescu & Collins, 2008). GNAS mutations
result in constitutive Gs? activation and elevated cAMP levels, which leads to excessive
bone matrix production in the skeleton and hormonal oveproduction in endocrine cells.
3.1.2 Other features of sporadic pituitary tumorigenesis
Other oncogenes that have been analyzed include proteins involved in signal transduction,
growth factors and their receptors, and cell cycle-related proteins. These, together with loss-
of-function events in TSGs and other players, are summarized in Table 6. A possible model
of pituitary tumorigenesis is presented in Figure 2.
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Regarding the gross chromosomal rearrangements observed in pituitary adenomas, the
published reports are relatively few and the results rather inconclusive. Overall, CGH, FISH,
and traditional cytogenetic studies have shown losses and gains of almost all chromosomes,
without definite trends (Bettio et al., 1997; Larsen et al., 1999; Kontogeorgos et al., 1999; Finelli
et al., 2000; Bello et al., 2001). Such aberrations are more frequent among secreting than
NFPAs, with higher incidence in invasive/recurrent tumors than the non-invasive ones. The
rarity of pituitary carcinomas does not facilitate valid conclusions concerning somatic gross
chromosomal defects and the carcinoma pathogenesis (DeLellis et al., 2004).
Finally, late advances in molecular biotechnology have facilitated the search for novel
candidate genes involved in pituitary tumorigenesis. Microarray-based differential gene
expression profiles have been recently generated for different types of human pituitary
adenomas (Evans et al., 2001; Morris et al., 2005; Moreno et al., 2005; Ruebel et al., 2006).
Table 6. Genetic alterations in sporadic pituitary tumorigenesis (modified from Asa & Ezzat,
2002; Lania et al., 2003; DeLellis et al., 2004; Boikos & Stratakis, 2007).
Gene Alteration in the tumors Type of pituitary adenoma
Gain-of-function events
Signal Transduction
Gs? (gsp) Activating somatic mutations GH-secreting
Gi?? Activating somatic mutations NFPAs (i)
RAS Activating somatic mutations Pituitary carcinomas (metastatic)
PKC Activating somatic mutations GH-secreting, invasive tumors (i)
PKA Loss of function of PRKAR1A due to germline
inactivating mutations
GH-secreting
Growth factors and their receptors
FGFR4
ptd-FGFR4
Alternative transcription initiation
Constitutive activation
All types
All types
TGF-? Overexpression PRL-, GH/PRL-, ACTH-secreting
Cell cycle
Cyclin D1 Overexpression Aggressive adenomas, NFPAs
Cyclin E Overexpression ACTH-secreting
PTTG Overexpression All types
HMGA2 Overexpression GH- and PRL-secreting
Loss-of-function events
TSGs
PRB LOH of 13q
Underexpression due to promoter methylation
Aggressive adenomas, carcinomas
CDKN2A/p16INK4A Underexpression due to promoter methylation All types, GH-secreting (i)
CDKN1B/p27Kip1 Underexpression due to protein degradation ACTH-secreting, recurrent tumors
and carcinomas
MEN1 Somatic inactivating mutations (rare) and LOH PRL-, GH- PRL/GH-, ACTH-secreting
and NFPAs
CDKN2C/p18INK4C Underexpression NFPAs, PRL- and GH-secreting
Other players
D2R Underexpression Resistant PRL-secreting (i)
SSTR2/SSTR5 Underexpression Resistant GH-secreting
GADD45G Underexpression due to methylation NFPAs, PRL- and GH-secreting
MEG3A Underexpression due to methylation NFPAs
RAS, rat sarcoma oncogene; PKA/C, protein kinase A/C, FGFR4, fibroblast growth factor receptor 4; ptd-FGFR4,
pituitary-derived FGFR4; TGF-?, transforming growth factor ?; PTTG, pituitary tumor transforming gene;
HMGA2, high mobility group at-hook 2; PRB, retinoblastoma protein; CDKN, cyclin-dependent kinase inhibitor;
D2R, dopamine D2 receptor; SSTR, somatostatin receptor; GADD45?, growth arrest and DNA-damage-inducible
protein gamma; MEG3A, maternally expressed protein 3A; (i): infrequently.
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Figure 2. Possible pathways of pituitary tumorigenesis. A) If genetic or epigenetic alterations
occurring in a pituitary cell confer growth advantage (e.g. PRKAR1A mutations or constitutive
activation of gsp leading to increased cAMP levels, loss of menin, methylation of p16 or p18), clonal
expansion  in  a  permissive  environment  (stimulatory  hormones  or  growth  factors)  can  lead  to
adenoma development. Additional genomic changes (e.g. loss of pRB, loss of p27, PTTG
overexpression) can lead to more aggressive (invasive) adenomas, or rarely (e.g. RAS mutations) to
metastatic carcinomas. B) Deregulated pituitary exposure to hypothalamic hormones (e.g. increase of
the GHRH/CRH/GnRH stimulatory effect or decrease of the dopamine/somatostatin inhibitory effect)
may lead to mild hyperplasia, followed by a series of possible events as described in A). Both
pathways are presented, despite the lack of clarity as to whether hyperplasia necessarily preceeds
pituitary adenoma formation (modified from Asa & Ezzat, 1998; Boikos & Stratakis, 2007).
3.2 Pituitary adenomas in familial endocrine-related tumor syndromes
The vast majority of pituitary adenomas occur sporadically (95%). Familial pituitary tumors
account for approximately 5% of all pituitary adenomas (Marx and Simonds, 2005; Daly et
al., 2007b). These tumors arise as a component of endocrine-related tumor syndromes,
namely Multiple Endocrine Neoplasia type I (MEN1), Carney complex (CNC), Isolated
Familial Somatotropinomas (IFS), and Familial Isolated Pituitary Adenomas (FIPA), which
are detailed below.
3.2.1 Multiple Endocrine Neoplasias
3.2.1.1 Multiple Endocrine Neoplasia type I (MEN1)
Multiple Endocrine Neoplasia Type 1 (MEN1) (MIM 131100) is a rare (~1:30.000) autosomal
dominant tumor susceptibility syndrome, characterized by varying combinations of
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parathyroid hyperplasia or adenomas (90-95%), tumors of the enteropancreatic
neuroendocrine tissues (30-75%), and adenomas of the anterior pituitary gland (10-60%)
(Brandi et al., 2001). Primary hyperparathyroidism is the first clinical manifestation of the
disease, present in more than 90% of the cases. Gastrinomas and insulinomas are the typical
enteropancreatic neuroendocrine tumors, encountered in 40% and 10% of MEN1 cases,
respectively. PRL-secreting adenoma is the most common pituitary adenoma type (20% of
cases), whereas GH-secreting adenomas are less frequent (~10% of cases) (Thakker, 1998;
Brandi et al., 2001). Other less common phenotypic features include lipomas,
angiomyolipomas, angiofibromas, colalgenomas, carcinoid tumors, and adrenocortical
adenomas (Chandrasekharappa et al., 1997; Thakker, 1998). Symptoms in MEN1 are mainly
caused by the overproduction of specific hormones, tumor mass effects, malignancy, or any
combination of these (Lemos & Thakker, 2008).
Familial MEN1 is defined as the occurrence of at least two of the three main MEN1-related
lesions in an individual, with at least one first-degree relative having clinical, radiological,
and/or surgical evidence, or repeated biochemical evidence of at least one of the MEN1-
related lesions (Brandi et al., 2001). MEN1 exhibits an equal sex distribution (Teh et al., 1998)
and a high age-related penetrance, with more than 95% of the patients being symptomatic
by the fifth decade of life (Trump et al., 1996).
In 1988, the MEN1 susceptibility gene was mapped on chromosomal region 11q13 (Larsson
et al., 1988) and positionally cloned nearly ten years after (Chandrasekharappa et al., 1997).
MEN1 spans a region of approximately 9 kb, has 10 exons, and encodes a 610 aa protein
termed “menin” (Marx, 2005). The overwhelming number of loss-of-function mutations,
together with LOH as the second mutational hit in MEN1-related tumors, leaves little doubt
that MEN1 represents a classical TSG, according to Knudson’s two-hit hypothesis.
Approximately 70-90% of typical MEN1 families carry pathogenic MEN1 mutations
(Agarwal et al., 1997; Teh et al., 1998; Giraud et al., 1998; Poncin et al., 1999a; Bergman et al.,
2000a; Cebrian et al., 2003, Klein et al., 2005; Ellard et al., 2005). No phenotype-genotype
correlations have been clearly recognized thus far (Agarwal et al., 1997; Tanaka et al., 1998a;
Teh et al., 1998; Giraud et al., 1998; Lemos & Thakker, 2008). Founder MEN1 mutations have
been identified (Agarwal et al., 1997) in families from Finland, Sweden, and France (Teh et
al., 1998; Giraud et al., 1998; Vierimaa et al., 2007). Bassett et al. (1998) estimated the age-
related penetrance from 47 unrelated MEN1 probands and their families as: Nonexistent in
individuals <5 years of age, 52% by the age of 20 years, >95% after the age of 40 years, and
complete at 60 years of age (Bassett et al., 1998). Such disease risk assessments have a great
impact on clinical evaluation, counseling, and management of at-risk individuals.
Sporadic MEN1 is defined as a MEN1 patient without known family history of any
endocrine manifestation (Brandi et al., 2001). Mutations in sporadic MEN1 cases have been
reported in 45-69% of the cases (Agarwal et al., 1997; Teh et al., 1998; Giraud et al., 1998;
Bassett et al., 1998; Tanaka et al., 1998b; Poncin et al., 1999b; Hai et al., 2000; Cebrian et al.,
2003; Ellard et al., 2005). Somatic MEN1 mutations are rather common among MEN1-related
sporadic tumors, such as parathyroid adenomas and enteropancreatic tumors (reviewed in
Lemos & Thakker, 2008), but are rare among non-MEN1 sporadic pituitary adenomas
(Zhuang et al., 1997a; Tanaka et al., 1998b; Prezant et al., 1998; Schmidt et al., 1999; Poncin et
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al., 1999b; Bergman et al., 2000b). It also seems that menin gene expression remains intact in
most sporadic pituitary adenomas, indicative of a lack of promoter mutations or
hypermethylation (Asa et al., 1998).
To date more than 560 unique germline or somatic mutations have been described, scattered
throughout the genomic MEN1 sequence, with only a few potential “hot spots”. The
majority or these mutations (80%) cause menin truncation, leading to lack of interaction
domains and the nuclear localization signals (NLSs), or absence of a translated product
because of nonsense-mediated mRNA decay (NMD) (Lemos & Thakker, 2008; The Human
Gene Mutation Database, May 2008 at www.hgmd.org).
Menin is a 67 kDa ubiquitously expressed protein, located in the nucleus due to three NLSs
(La et al., 2006), and binds directly or indirectly to at least 21 candidate molecules or
complexes (reviewed in Agarwal et al., 2004). Recent data support a functional role of menin
at cell division and proliferation, apoptosis, transcriptional regulation, or genomic stability
(reviewed in Marx & Simonds, 2005). Men1-/- mice are embryonic lethal or have severe
developmental abnormalities (Crabtree et al., 2001; Bertolino et al., 2003a; Loffler et al., 2007),
whereas Men1+/- mice have proved an excellent model of MEN1 disease; these mice develop
major MEN1-related lesions, albeit with certain differences from human MEN1 (Crabtree et
al., 2001; Crabtree et al., 2003; Bertolino et al., 2003b; Loffler et al., 2007). Pituitary- and
pancreas-specific Men1-knockout mice exhibit normal pancreatic and pituitary
development, but pancreatic hyperplasia and prolactinomas develop eventually, as in
human MEN1 (Biondi et al., 2004).
3.2.1.2 MEN1-like (MEN4)
The identification of the MEN1 gene has made genetic diagnosis possible in a great number
of patients suspected for this syndrome. Yet, a rather intriguing subset of suspected familial
cases, varying between 10-25%, test negative for mutations in the MEN1 coding region
(Agarwal et al., 1997; Bassett et al., 1998; Giraud et al., 1998; Hai et al., 2000; Cebrian et al.,
2003; Ellard et al., 2005; Klein et al., 2005). Interestingly, these families do not exhibit
significant phenotypic differences when compared to MEN1 mutation-positive families
(Bassett et al., 1998). It is likely that mutations outside the coding region (i.e. promoter,
untranslated regions, and intronic regions) or possible disease-associated SNPs of yet
undetermined significance escape identification. Disease phenocopies, not caused by MEN1
mutations, have also been reported (Burgess et al., 2000; Hai et al., 2000; Klein et al., 2005).
Nonetheless, theoretically, MEN1 may exhibit genetic heterogeneity, with other
predisposing genes harboring pathogenic mutations.
Recently, Pellegata et al. (2006) identified Cdkn1b, which encodes the cyclin-dependent
kinase inhibitor (Cdk) p27Kip1, as the gene predisposing to a MEN-like phenotype (MENX) in
a rat model (Pellegata et al., 2006). The animals exhibited phenotypic overlap of both MEN1
and MEN2 (bilateral pheochromocytomas, parathyroid adenomas, thyroid hyperplasia,
paragangliomas, and endocrine pancreas hyperplasia) in an autosomal recessive pattern of
inheritance. Affected rats were found homozygous for a tandem Cdkn1b duplication of 8 bp
that resulted in frameshift and a premature termination codon. p27Kip1–deficient rats showed
increased body weight compared to their wild type littermates (Fritz et al., 2002; Pellegata et
Genetic Basis of Pituitary Adenoma Predisposition
32
al., 2006). This rat model was very similar to Cdkn1b-knockout mice: These mice displayed a
20-30% increase in body weight, as well as multiple organ hyperplasia, and pituitary
intermediate lobe adenomas as the sole tumor phenotype (Nakayama et al., 1996; Kiyokawa
et al., 1996; Fero et al., 1996).
Based on the rat MENX model, a heterozygous germline nonsense mutation was
subsequently identified in the human MEN1-like (MEN4) (MIM 610755) predisposing gene,
namely CDKN1B (12p13), which spans a 5 kb region, is composed of 3 exons, and codes for a
198 aa protein.  The mutation was identified in a patient suspected for MEN1 (acromegaly,
pituitary adenoma, and primary hyperparathyroidism), but tested negative for MEN1
mutations. The mutation was segregating in the patient’s family, with several family
members exhibiting endocrine neoplasia. Functional studies clearly established an
association between CDKN1B as a novel putative TSG and this heritable endocrine-related
neoplasia syndrome (Pellegata et al., 2006).
Since CDKN1B gene identification, a heterozygous germline duplication of 19 bp has been
detected in a patient clinically suspected for MEN1 (hyperparathyroidism, Cushing’s
disease, and small-cell neuroendocrine cervical carcinoma). First-degree relatives were free
of MEN1-related lesions, but due to lack of extensive family history, it was not possible to
establish whether this was a truly familial or sporadic case (Georgitsi et al., 2007). CDKN1B
mutations have not been found in cases of familial acromegaly, familial isolated pituitary
tumors, familial hyperparathyroidism, or familial MEN1 (Ozawa et al., 2007; Georgitsi et al.,
2007; Owens et al., 2008; Igreja et al., 2008; Vierimaa et al., submitted manuscript). Recently,
three novel mutations (P95S, 5’UTR -7G>C, and stop>Q) were reported in three suspected
MEN1 families with parathyroid and other endocrine lesions, but, interestingly, without
pituitary involvement (Dr. Agarwal, oral communication at the 11th International Workshop
on MEN, Delphi, Greece, 2008).
Finally, regarding sporadic endocrine neoplasia, germline CDKN1B mutations are a very
rare cause of MEN1 (Owens et al., 2008; Igreja et al., 2008), whereas the MEN1 variant of
parathyroid/pituitary tumors (Hai et al., 2000) seems to occur due to genetic causes other
than CDKN1B (Ozawa et al., 2007). This is likely also the case for sporadic GH-secreting
adenomas (Georgitsi et al., 2007), and other types of pituitary tumors (Takeuchi et al., 1998;
Dahia et al., 1998). Yet, it should be noted that CDKN1B/p27Kip1 protein expression levels,
and not mRNA levels, are significantly reduced during progression from normal to
neoplastic pituitaries, suggesting a contribution of CDKN1B/p27Kip1 in sporadic pituitary
tumorigenesis by posttranslational mechanisms (Takeuchi et al., 1998; Dahia et al., 1998;
Lidhar et al., 1999; Bamberger et al., 1999; Pellegata et al., 2006).
CDKN1B/p27Kip1 protein plays an important role in the cell cycle regulation, through the
binding and inhibition of cyclin/CDK complexes during the cellular G1 to S phase transition
(Sherr & Roberts, 1999); thus, CDKN1B/p27Kip1 participates in determining several cell fate
decisions, including proliferation, differentiation, apoptosis, cell density, and even cell
migration (Besson et al., 2004; Chu et al., 2008). Interestingly, it has been shown that CDKN1B
is a transcriptional gene target of menin (Karnik et al., 2005), a possible target of the
oncogenic RET protein in endocrine cells (Drosten et al., 2004), as well as a direct
transcriptional target of aryl hydrocarbon receptor (AHR), as detailed later (Kolluri et al.,
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1999) (see Discussion, section 6.2). These data indicate that functionally disrupted
CDKN1B/p27Kip1 is likely to play a role in endocrine tumorigenesis.
3.2.2 Carney Complex (CNC)
Carney complex (CNC) (MIM 160980) is a rare autosomal dominant disease manifested by
spotty-skin pigmentation, cardiac and other myxomas (tumors of the connective tissue),
endocrine tumors (mainly GH-secreting adenomas), and schwannomas (benign tumors of
the myelin sheath) (Carney et al., 1985). The pituitary presentation of CNC is essentially
limited to mammosomatotroph hyperplasia that may progress to adenoma (Pack et al.,
2000). Clinically manifested acromegaly is encountered in approximately 10% of CNC
patients, despite the fact that up to 75% of them have altered GH/IGF-I and PRL levels (Pack
et al., 2000; Stratakis et al., 2004).
In 70% of CNC cases a genetic causation has been identified, with two susceptibility loci,
one on chromosome 17q24 and the second on chromosome 2p16 (Stratakis et al., 1996;
Kirschner et al., 2000a). The former locus was found to harbor the predisposing gene protein
kinase A type I-alpha regulatory subunit (PRKAR1A), which covers a genomic region of
approximately 21 kb, is comprised of 11 exons, and encodes a 381 aa protein. PRKAR1A
codes for a serine/threonine protein kinase A (PKA) regulatory subunit that is the main
mediator in cAMP signalling. Inactivating PRKAR1A mutations have been identified in up
to 60% of CNC patients meeting the diagnostic criteria (Kirschner et al., 2000a). CNC is a
highly penetrant disease, with expression typically manifested by the age of 20 years. No
gene has been identified in the second susceptibility locus (2p16), which has been restricted
to a 100 kb region (Stratakis et al., 1996).
Almost all 40 distinct germline PRKAR1A mutations reported thus far, lead to mRNA
instability and NMD, and thus, decreased or absent expression of the mutant protein
(Kirschner et al., 2000a; 2000b; Groussin et al., 2002). Mutations that escape NMD result in
the retention of abnormal PRKAR1A and increased PKA activity, leading to typical
manifestations of CNC (Greene et al., 2008). These alterations do not appear to occur on
mutation “hot spots” (Kirschner et al., 2000b; Sandrini & Stratakis, 2003). LOH at 17q22-q24
has been demonstrated in CNC-associated pituitary tumors (Bossis et al., 2004). Somatic
PRKAR1A mutations have not been detected in sporadic pituitary tumors, indicating that
PRKAR1A is not prominently involved in sporadic pituitary tumorigenesis (Kaltsas et al.,
2002; Sandrini et al., 2002; Yamasaki et al., 2003).
The functional inactivation of PRKAR1A protein results in excess PKA signalling and
elevated cAMP levels in the affected tissues (Groussin et al., 2002). Ablation of both Prkar1a
copies in mice results in embryonic lethality (Amieux et al., 2002). Contrary, Prkar1a+/-  mice
and transgenic mice with an antisense Prkar1a exon 2 construct develop features compatible
with the CNC phenotype, without, however, marked pituitary disease (Griffin et al., 2004a;
Griffin et al., 2004b; Kirschner et al., 2005). The recently reported pituitary-specific knockout
mice (pitKO), in which Prkar1a is deleted from the GH/PRL/TSH cell lineage, develop GH-
secreting tumors by 18 months of age, with moderate frequency. Many pitKO mice show
marked serum GH elevation, despite the lack of frank tumors, which is analogous to human
CNC (Yin et al., 2008).
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3.2.3 Isolated Familial Somatotropinomas (IFS)
By definition, IFS (MIM 102200) describes the occurrence of two or more cases of
acromegaly or gigantism in a family in the absence of MEN1 or CNC (Gadelha et al., 1999).
Reports on familial acromegaly/gigantism date back to the early 1970s and 1980s (Levin et
al., 1974; Kurisaka et al., 1981; Jones et al., 1984; Abbassioun et al., 1986). The notion that
familial acromegaly/gigantism represents a rare entity, distinct from MEN1, became clearer
with the accumulation of reports on first-degree relatives diagnosed with GH-secreting
adenomas without mutations in MEN1 or GNAS (Pestell et al., 1989; McCarthy et al., 1990;
Tamburrano et al., 1992; Links et al., 1993; Matsuno et al., 1994; Benlian et al., 1995; Verloes et
al., 1999; Ackermann et al., 1999). An autosomal dominant inheritance pattern with
incomplete penetrance was proposed (Pestell et al., 1989; Tamburrano et al., 1992; Benlian et
al., 1995; Verloes et al., 1999; Gadelha et al., 1999).
In sporadic GH-secreting adenomas, LOH of 11q13 has been detected in as many as 10-40%
of tumors (Thakker et al., 1993; Boggild et al., 1994; Zhuang et al., 1997a; Simpson et al., 2003);
however, such allelic imbalance was very rarely seen in concert with somatic inactivating
MEN1 mutations (Boggild et al., 1994; Zhuang et al., 1997a; Prezant et al., 1998; Tanaka et al.,
1998b; Schmidt et al., 1999). The same phenomenon had been observed in many studies that
aimed at identifying the predisposing locus for familial GH-secreting adenomas in families
with acromegaly and gigantism: Genome-wide LOH studies on tumor DNA confirmed loss
of one allele on 11q13, but patients did not carry germline MEN1 mutations, whereas the
menin expression in the tumors was normal (Yamada et al., 1997; Kakiya et al., 1997; Teh et
al., 1998; Tanaka et al., 1998a; Gadelha et al., 1999; Ackermann et al., 1999). In 2000, Gadelha et
al. established linkage of the IFS locus on 11q13. This and subsequent studies restricted the
candidate IFS 11q13 locus, still without making the exclusion of MEN1 possible. At the time,
mutations in the promoter region, introns, untranslated regions, or hypermethylation of
promoter CpG islands of MEN1 could not be excluded (Gadelha et al., 2000; De Menis &
Prezant, 2002). Also linkage of IFS to chromosomes 2 and 17 (PRKAR1A locus) was excluded
(Gadelha et al., 2000; Frohman & Eguchi, 2004). The number of reported IFS families
continued to increase (Jorge et al., 2001; De Menis & Prezant, 2002; Tamura et al., 2002;
Luccio-Camelo et al., 2004; Tiryakioglu et al., 2004; Soares et al., 2005), with approximately 50
IFS families reported by 2006 (Daly et al., 2006b).
Based on reports on IFS families by the year 2004, a number of important conclusions could
be drawn regarding the IFS characteristics: The clinical manifestations of IFS were similar to
those seen in patients with sporadic GH-secreting adenomas; macroadenomas surpassed
microadenomas, gigantism was reported, and half of all GH-secreting adenomas were also
immunopositive for PRL. Most of the families were represented by two affected cases. On
the other hand, the median age at diagnosis in IFS was 25 years, and the age at onset was
<30 years in roughly three quarters of the patients. This was contrasted to sporadic
acromegaly, with an age of onset at the forth or fifth decade of life. Lastly, a slight
preponderance of male versus female patients (1.5:1) was noted (Soares & Frohman, 2004;
Frohman & Eguchi, 2004).
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It was eventually concluded that loss-of-function of a TSG distinct from MEN1 was
responsible for IFS. Apart from MEN1, GHRH receptor, GNAS, and PRKAR1A, other genes
residing in 11q13 had been excluded as candidates in patients with IFS (Soares et al., 2005).
3.2.4 Familial Isolated Pituitary Adenomas (FIPA)
Until recently, literature on families encompassing different types of pituitary adenomas,
outside the contexts of MEN1, CNC, or IFS, had been scarce (Himuro et al., 1976; Yuasa et al.,
1990; Stock et al., 1997). Familial prolactinoma was reported by Berezin and Karasik (1995),
whereas hereditary early-onset prolactinoma was already known in a rat model (Chedid et
al., 1988), the only animal model exhibiting genetic susceptibility to pituitary adenomas at
the time.
Recently, a distinct clinical entity, namely Familial Isolated Pituitary Adenomas (FIPA)
(MIM 102200), was reported in order to characterize families with isolated pituitary
adenomas outside the clinical and genetic contexts of MEN1 and CNC (Daly et al., 2005). The
initiative – undertaken by the Department of Endocrinology, University of Liège, in
Belgium, as an international, collaborative effort – resulted in a collection of 64 families that
exhibited different patterns of pituitary adenomas among 138 affected individuals (Daly et
al., 2006b). Families with up to four affected cases were reported (Daly et al., 2006b; Beckers
& Daly, 2007); they were characterized either as “homogeneous” (same adenoma phenotype
among affected cases) – including 12 IFS families – or “heterogeneous” (different adenoma
phenotypes among affected members). FIPA cases were significantly younger at diagnosis
than population-matched sporadic cases. Prolactinomas were the predominant adenoma
type, but not as frequent as in familial MEN1; females were affected more often than males,
reflecting the fact that prolactinomas are encountered more often in females; GH-secreting
adenomas were seen much more often in FIPA than MEN1 or sporadic pituitary adenomas
(Daly et al., 2006b).
This initial study indicated that FIPA may account for 2.5% of pituitary adenomas (Daly et
al., 2006b), similar to the estimate that 2.7% of pituitary adenomas are due to familial MEN1
(Scheithauer et al., 1987). Thus, and including the few CNC and IFS cases known worldwide,
it was suggested that hereditary tumor susceptibility may contribute to pituitary
tumorigenesis by approximately 5% (Marx & Simonds, 2005; Daly et al., 2007c).
A first-degree relationship between affected members was observed in the majority of the
FIPA kindreds. Thus, based on pedigree analysis, an autosomal dominant inheritance
pattern with incomplete penetrance was suggested for FIPA, as previously hypothesized for
IFS (Daly et al., 2006b). However, the exact genetic cause remained elusive.
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AIMS OF THE STUDY
The primary aim of the present work was
1. To localize and identify a novel tumor susceptibility gene that causes Pituitary
Adenoma Predisposition (PAP) in familial and sporadic cases from Northern Finland
(I).
Subsequently from gene identification, we envisaged the following aims:
2. To gain insights into the genetic basis of PAP in an effort to establish molecular
diagnosis (II) by:
a)  Studying the contribution of PAP in pituitary adenoma patients of various
ethnic origins,
b)  Further elucidating the PAP phenotype, and
c)  Testing the potential of immunohistochemistry as a diagnostic tool.
3. To examine whether and to what extent the PAP gene is implicated in the
tumorigenesis of common tumor types (III).
4. To examine whether pediatric onset pituitary tumorigenesis is attributed to tumor
susceptibility caused by mutations in the PAP gene (IV).
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SUBJECTS AND METHODS
1. Subjects
1.1 Familial cases (I)
Three familial clusters of pituitary adenoma patients had been detected in Northern Finland.
Genealogy analysis established linkage between two of these clusters, whereas the third
appeared separate. Altogether, 11 affected individuals were identified in an impressively
large pedigree (Fig. 3A), hereafter referred to as ‘family 1’. In the second pedigree, hereafter
referred to as ‘family 2’, two individuals were affected with gigantism (Fig. 3B). Overall,
DNA samples from 13 affected individuals (Table 7), seven obligatory carriers, and four key
unaffected relatives were obtained from both families. Paraffin blocks of embedded
pituitary tumor tissue were available from six of 13 affected cases. Apart from the two
Finnish families, three foreign families with two affected individuals each were included in
the study: Blood-extracted DNA was available from two Italian siblings with
acromegaly/gigantism, as well as from one Turkish and one German familial
somatotropinoma case (Table 7).
1.2 Other pituitary adenoma patient cohorts (I, II, IV)
Study I: A population-based cohort of 54 acromegaly patients, diagnosed with GH-secreting
adenomas between 1980 and 1999 in Oulu University Hospital, Northern Finland, had been
previously characterized (Kauppinen-Makelin et al., 2005). Of these, material from 45
patients became available, either as blood sample or paraffin-embedded normal or tumor
tissue blocks. In addition to the population-based cohort, 10 unselected Finnish sporadic
acromegaly patients were included in the study (Table 7).
Study II: Four hundred and sixty pituitary adenoma patients were analyzed. This cohort
consisted of: a) 63 young acromegaly patients from Finland (different from study I) and
Germany; b) 71 unselected Italian acromegaly patients; c) 235 unselected pituitary adenoma
patients from USA and Poland; and d) 91 Dutch and Spanish patients counseled and
examined for MEN1, but negative for MEN1 mutations. A detailed description of these
cohorts is provided in publication II and Table 7. Genetic analysis of the young acromegaly
German samples was carried out at tumor DNA level; for all other samples, analysis was
performed on blood-extracted DNA. Familial history was revealed in two cases, one from
the German and one from the Spanish cohort. Tumor samples from the identified mutation
carrier patients were utilized if available.
Study IV: The material of this study consisted of blood-extracted DNA samples from a
population-based cohort of 36 pediatric Italian, sporadic pituitary adenoma patients from
Italy, referred to two medical centers since 1988. Inclusion criteria for the cases were: 1)
either age at diagnosis less than 18 years, or clinical evidence of adenoma development
before the age of 18 years, and 2) no evidence of familial pituitary adenomas (Table 7).
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Table 7. Pituitary adenoma patients recruited in the studies of the present thesis work.
Subjects Number of
affected cases
Pituitary adenoma type of affected
cases (number of cases)
Selection criteria Study
Familial cases
Finland
Family 1
Family 2
11
2
GH- (n=4), GH/PRL- (n=2), PRL-
secreting (n=5)
GH-secreting (n=2)
Family history I
Italy 2 GH-secreting (n=2) Family history I
Germany 1 GH-secreting Family history I
Turkey 1 GH-secreting Family history I
Other cohorts
Finland 45 GH-secreting (n=45) Population-based
acromegaly patients
I
Finland 10 GH-secreting (n=10) Sporadic acromegaly
patients
I
Finland 36 GH-secreting (n=36) Young  (<45  yrs  at  dg)
sporadic acromegaly
patients
II
Germany 27 GH-secreting (tumor samples) (n=27) Young (<40 at op)
acromegaly patients
II
Italy 71 GH-secreting (n=71) Sporadic acromegaly
patients
II
USA 113 GH- (n=13), PRL- (n=11), ACTH-
secreting (n=13), NFPA (n=76)
None (all types of
pituitary adenomas)
II
Poland 122 GH- (n=30), ACTH-secreting (n=74),
NS (n=18)
None (all types of
pituitary adenomas)
II
Spain 55 GH- (n=18), GH/PRL- (n=2), PRL-
(n=5), ACTH-secreting (n=4), NFPA
(n=5)
Suspicion for MEN1 (all
types of pituitary
adenomas)
II
The Netherlands 36 GH- (n=6), PRL-secreting (n=6),
NFPA (n=1), NS (n=9)
Suspicion for MEN1 (all
types of pituitary
adenomas)
II
Italy 36 GH- (n=5), GH/PRL- (n=2), PRL-
(n=19), ACTH-secreting (n=3), NFPA
(n=7)
Pediatric onset (all types
of pituitary adenomas),
sporadic
IV
yrs, years; dg, diagnosis; op, operation; NS, not specified
1.3 Other tumor samples (III)
A total of 499 samples from three common tumor types were utilized: 373 fresh-frozen
colorectal tumor samples, chosen from a series collected between 1994 and 1998 (Aaltonen et
al., 1998, Salovaara et al., 2000); these samples displayed at least 50% tumor tissue, according
to a pathologist’s histological evaluation. Corresponding normal tissue had been previously
extracted from blood or normal colonic epithelium, distant from the tumor margins. A series
of 82 breast (Winqvist et al., 1995) and 44 prostate tumor DNA samples (Waltering et al.,
2006) were also analyzed.
1.4 Healthy controls (I, II, III, IV)
Overall, 749 unrelated, healthy individuals were available as population-matched healthy
controls. In detail, the cohort consisted of: 209 anonymous Finnish Red Cross blood donors,
288 Caucasians from United Kingdom (Human Random Control DNA panel, Porton Down,
Salisbury, Wiltshire, UK), 110 Caucasians from Centre d’Étude du Polymorphisme Humain
(Fondation Jean Dausset-CEPH, Paris, France), 52 Italians (Treviso General Hospital, Italy),
and 90 German individuals (Leipzig University, Germany).
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2. DNA/RNA extraction (I, II, III, IV)
DNA was extracted from peripheral EDTA-blood samples by a standard non-enzymatic
procedure (Lahiri & Nurnberger, 1991). Tumor DNA from fresh-frozen tissue samples
[colorectal, breast, and prostate tumors (study III)] had been previously extracted (Aaltonen
et al., 1998, Salovaara et al., 2000, Winqvist et al., 1995, Waltering et al., 2006). DNA from
paraffin-embedded pituitary adenomas and paraffin-embedded normal tissue was isolated
using a standard protocol (Kannio et al., 1996), or alternatively, a quick-extraction protocol
(Shibata et al., 1988). Total cellular RNA was extracted using the RNeasy kit (Qiagen Inc.,
Valencia, CA) and used for cDNA synthesis by reverse transcription PCR (RT-PCR),
according to a standard protocol (Promega Corporation, Madison, WI) (study I).
3. Disease locus identification (I)
3.1 SNP arrays
Whole-genome SNP genotyping was performed on peripheral blood-extracted DNA
samples from 16 individuals from family 1 (Fig. 3A, individuals A2, A5, A6, A9, A10, A11,
A13, A14, A16, A18, A20, A21, A31, A32, A33, and one healthy spouse). DNA was extracted
with the PureGene DNA isolation kit (PureGene, Gentra Systems, Minneapolis, MN).
Genotyping was carried out on an Affymetrix Human Mapping 50K Xba 240 SNP array
(Affymetrix Inc., Santa Clara, CA). Signal intensities were analyzed by the GeneChip DNA
analysis software (GDAS), version 3.0.2.8 (Affymetrix).
3.2 Linkage analysis
The SNP genotyping data were converted to appropriate linkage format by the
ALOHOMORA software (Ruschendorf & Nurnberg, 2005) and were subjected to quality
control routines, including gender check, graphical representation of relationship errors
(GRR) (Abecasis et al., 2001), and Mendelian errors (O'Connell & Weeks, 1998). All non-
informative markers were deleted before further analyses. Two alternative affected-only
analyses were performed: One with “high-stringency” criteria, considering only
acromegaly/gigantism as the disease phenotype (GH- or mixed GH/PRL-secreting
adenomas), and one with “low-stringency” criteria, considering all pituitary adenoma types
(GH-, GH/PRL-, and PRL-secreting adenomas) as the affected phenotype. This approach
was undertaken, because acromegaly/gigantism is a rare phenotype and phenocopies are
expected to be much more rare than the number of phenocopies for PRL-secreting
adenomas. Linkage calculations were performed with the Allegro and SimWalk2 softwares
(Gudbjartsson et al., 2000; Sobel & Lange, 1996; Sobel et al., 2001; Gudbjartsson et al., 2005)
and the results were visualized with HaploPainter V.024beta (Thiele & Nurnberg, 2005).
3.3 Fine mapping and haplotype analysis
Fine mapping studies of the candidate disease locus were performed on genomic DNA
samples isolated from blood or paraffin-embedded normal tissue from the affected familial
cases and the unaffected obligatory carriers, as well as from sporadic acromegaly cases. A
total of 30 published (Ensembl Genome Browser and NCBI) and novel microsatellite
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markers from chromosomal region 11q12.2-11q13.3 (physical location 61.4-69.0 Mb) were
analysed. The novel markers were identified using the Tandem Repeats Finder program
(Benson, 1999) (http://tandem.bu.edu/trf/trf.html). In addition, six informative SNP-markers
from the Human Mapping 50K Xba 240 SNP array mapping to the region of interest were
utilized (Table S1 in the supporting material of publication I). These SNPs were selected on
the basis of the significance of the difference in genotype frequency between the affected
cases versus 42 unrelated Finnish samples previously genotyped with the same platform but
for a different project. Microsatellite and SNP marker polymerase chain reaction (PCR)
products were run on an ABI3730 sequencer (Applied Biosystems, Foster City, CA).
Microsatellite alleles were viewed and scored with the GeneMapper v.3.7 software (Applied
Biosystems). The haplotypes were constructed manually. Two unrelated CEPH individuals
(1347-2 and 1347-13) were used as internal controls in all fine-mapping experiments.
The most informative markers in the shared region (Table S1 in the supporting material of
publication I) were selected for the overall parametric linkage calculations in families 1 and
2, using the SimWalk2 software. Linkage analysis was again performed for “high-
stringency” and “low-stringency” criteria. With the exception of the affected individuals, all
the others were considered of unknown phenotype. The disease model parameters were:
Disease allele population frequency 0.001, penetrance for heterozygous and homozygous
disease genotypes 0.1, phenocopies for acromegaly/gigantism 0.0002, and phenocopies for
any pituitary adenoma 0.01.
3.4 Gene expression profiling
3.4.1 Gene expression microarrays
Expression profiles were generated by the Human Genome U133 Plus 2.0 expression arrays
(Affymetrix). Blood-derived total RNA samples were obtained from 16 individuals: Nine
affected/obligatory carriers, segregating a disease haplotype, (Fig. 3A and 3B, A2, A6, A8,
A14, A16, A18, A20, A21, A22 from families 1 and 2) and seven controls: Five unrelated
spouses from families 1 and 2 and two identically and simultaneously processed samples
from another project. All experimental procedures were performed according to the
manufacturer’s recommendations (Affymetrix).
3.4.2 Data analysis
The quantitative expression data were normalized by scaling all chips to the average gene
expression data of all 16 chips. The expression of each probe set was divided by the mean
expression of that probe across all the samples, so that the resulting mean expression for
every probe was 1. The normalized expression data were filtered using the Affymetrix
Detection Algorithm which assigned flag calls (as ‘present’, ‘absent’, or ‘marginal’), in order
to remove expression values below detectable levels. Subsequent analyses were restricted to
probe sets with detectable expression in a sufficient number of samples to allow a Student’s
t-test between the affected/obligatory carriers and control groups. Data normalization and
filtering analyses were performed using GeneSpring 7.0 software (Silicon Genetics,
Redwood City, CA).
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4. Genetic analysis (I, II, III, IV)
4.1 Mutation screening by direct sequencing
Genetic analyses were performed by PCR and direct genomic DNA sequencing. For primer
design, genomic sequences were retrieved from the University of California Santa Cruz
(UCSC) Genome Browser (http://genome.ucsc.edu/cgi-bin/hgGateway, version May 2004)
and primers were designed by the use of the publicly available softwares ExonPrimer
(http://ihg2.helmholtz-muenchen.de/ihg/ExonPrimer.html) and Primer3
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). Primer sequences are provided
in Table S4 in the supporting material of publication I.
PCR reactions were performed at optimized conditions, according to standard procedures.
The  basic  protocol  was  modified  depending  on  the  DNA  sample  (blood-  or  paraffin-
extracted DNA), the primer annealing temperatures, and the amplification outcome of the
template. PCR products were purified from residual primer oligonucleotides and
unincorporated dNTPs by ExoSAP-IT (USB Corporation,  Cleveland, OH),  according to the
manufacturer’s instructions. Sequencing was performed using the BigDye3.1 termination
chemistry on an ABI3730 sequencer (Applied Biosystems). Sequencing chromatograms were
visualised and aligned to the wild type reference sequence(s) using the BioEdit Sequence
Alignment Editor software (http://www.mbio.ncsu.edu/BioEdit/BioEdit.html) (Ibis
Biosciences, Carlsbad, CA). All observed sequence changes were confirmed on independent
experiments. All findings on pituitary tumor DNA level were examined on the
corresponding normal tissue DNA, if available, and vice versa.
All mutations and variants have been annotated according to the nomenclature for human
genomic sequence variations (den Dunnen & Antonarakis, 2001; The Human Genome
Variation Society 2008, at www.hgvs.org).
4.2 Loss of heterozygosity (LOH) study
Before gene identification, LOH was partially assessed by tumor-DNA microsatellite marker
analysis (selected from the panel of 30 markers used for fine-mapping purposes), in four
familial cases bearing the Finnish founder haplotype and two sporadic cases. For each tumor
individually, the most polymorphic markers were selected. LOH was concluded when the
marker alleles segregating with the affected haplotype were retained, whereas the
corresponding wild type alleles were significantly reduced or lost (unpublished data). LOH
on tumor-derived DNA was assessed by visual observation of the sequence chromatograms
by comparing the peak heights/areas between the wild type and mutant allele. Allelic loss
was concluded when the wild type allele was either completely or nearly completely
invisible, or significantly reduced when compared to the mutant allele.
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5. Immunohistochemistry (IHC) (I, II, IV)
IHC staining of familial and sporadic pituitary adenomas for hypophyseal hormones (GH,
PRL, ACTH, FSH, LH, and TSH) was performed according to standard procedures (Table S5
in the supporting material of publication I). For AIP detection (studies II and IV), the mouse
polyclonal antibody SP5213P (Acris Antibodies, Hiddenhausen, Germany) was used at a
1:4000 dilution. All IHC laboratory procedures are detailed in the original publications. IHC
stainings were performed at the Department of Pathology, University of Oulu, and
evaluation was carried out by a pathologist.
6. In silico analysis (II, III, IV)
The potential effect on splicing of previously unreported AIP variants of undetermined
significance (silent or missense changes, intronic variants) was tested in silico by
computational methods with freely available softwares (NetGene2, the Berkley Drosophila
Genome Project, Alternative Splice Site Predictor, and SpliceScan; for the corresponding
websites see list of references on page 93). For protein alignments, the human AIP protein
sequence and its homologues in other species were retrieved from the UCSC Genome
Bioinformatics database (version March 2006) and from the Ensembl Genome Browser
(version 38, April 2006). Alignments were performed by the BioEdit Sequence Alignment
Editor software.
7. Ethical issues
The study was approved by the Ministry of Social Affairs and Health and the Ethics Review
Committees of the Hospital District of Helsinki and Uusimaa, and the Department of
Medical Genetics of the University of Helsinki. Samples were used after informed consent of
the patients or their parents. Relatives of patients were contacted only through the patients.
Tumor samples were obtained with authorization by the National Authority for Medicolegal
Affairs.
Genetic Basis of Pituitary Adenoma Predisposition
43
RESULTS
1. Pituitary Adenoma Predisposition (PAP) gene identification (I)
1.1 PAP locus maps on chromosome 11q13
Previously, three familial clusters of pituitary adenoma cases had been detected in Northern
Finland (Oulu region) (Fig. 3). The first cluster displayed three cases of acromegaly or
gigantism (Fig. 3A, individual A13, affected by a mixed GH/PRL-secreting adenoma, and
individuals A13 and A31 affected by GH-secreting adenomas). The second cluster consisted
of two patients; one had been diagnosed with mixed GH/PRL-secreting adenoma, and the
other with PRL-secreting adenoma (Fig. 3A, individuals A14 and A21). The third cluster
consisted of two distantly related patients with gigantism (Fig. 3B, individuals A8 and A34).
In 2004, a third individual from the first cluster was diagnosed with gigantism (Fig. 3A,
individual A33). This realization prompted the hypothesis that, at least in this cluster,
genetic pituitary adenoma predisposition (PAP) is likely to be present, since acromegaly is a
rare disease (Alexander et al., 1980; Bengtsson et al., 1988; Kauppinen-Makelin et al., 2005).
Later, the first and second clusters were linked by genealogy (family 1), whereas the third
appeared separate (family 2). For PAP gene identification purposes, the relevant members of
families 1 and 2 were invited to participate in the study.
For the identification of the putative disease predisposition locus, segregating in family 1,
we performed linkage analysis on SNP chip genotyping data from 16 individuals. For the
genome-wide parametric and non-parametric multipoint linkage calculations, family 1 had
to be divided into three separate branches, since linkage programs were not suitable for
performing analyses of large number of markers in such a large pedigree. LOD scores were
calculated separately for each branch and then added together by loci. In the genome-wide
search, the highest parametric LOD score of 3.9 was detected for the “high-strigency”
criteria (acromegaly or gigantism, 6 individuals) for chromosome 11 at 68.4-73.6 cM. This
region, which also includes the MEN1 gene, had been previously suggested to harbor a
putative TSG for IFS. In addition to chromosome 11, other regions displaying significant
linkage were on chromosomes 4 (3.15), 5 (3.21), and 8 (3.08). Non-parametric linkage results
were compatible with the parametric analysis. Next, the whole family 1 was reanalyzed as
one pedigree, in the regions displaying LOD scores over 3.
In order to evaluate the effect of linkage disequilibrium (LD) in regions with LOD scores
over 3, the data were further analyzed with reduced marker density (< 0.1 cM). Prior to LD
removal, LOD scores over 3 were observed for chromosomes 4 (5.61) and 11 (7.5) for the
“high-stringency” criteria, and for chromosomes 4 (2.99), 11 (6.3), and 14 (3.59) for the “low-
stringency” criteria. The only significant LOD score after LD removal was obtained for
chromosome 11 in the parametric linkage analysis. Haplotype construction of family 1
individuals finally placed the PAP locus between SNPs rs174449 (i.e. last non-linked SNP
upstream) and rs1938685 (i.e. first non-linked SNP downstream) (11q12.2-q13.3, 61.4-69.0
Mb, Ensembl, release 36-Dec2005).
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Figure 3. Pedigrees of the two Finnish families with pituitary adenomas that facilitated the
identification of the AIP gene. (A) Family 1, (B) Family 2. The pedigrees have been modified to ensure
confidentiality. Individuals are indicated with their coded names (A2, A5, A6, etc). Number of
offspring is indicated by Arabic numerals, enclosed in diamond symbols. Generations are indicated
by Roman numerals, on the left side.
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1.2 Candidate locus fine-mapping reveals a founder haplotype of ~7 Mb
Figure 4. Founder haplotype spanning ~7 Mb.
Fine-mapping placed the candidate locus
between markers acro_chr11_2 and
acro_chr11_37 (grey vertical bar). Known
microsatellite markers are indicated in black
color, whereas novel microsatellite markers
are shown in blue. Linked SNPs are shown in
purple. The MEN1 and AIP loci  are  indicated
in relation to neighboring markers.
Further characterization of the linked
haplotype was performed with 30
microsatellite and six SNP markers. The
most informative markers in the shared
region were used for parametric linkage
calculations in families 1 and 2. The added
maximum LOD scores were 8.3 (7.5 for
family 1 and 0.8 for family 2) for the
“high-stringency” criteria, and 7.1 (6.3 for
family 1 and 0.8 for family 2) for the “low-
stringency” criteria. The linked founder
haplotype (Fig. 4) segregated perfectly in
families 1 and 2 with the GH- and
GH/PRL-secreting adenoma phenotype
(acromegaly). Although significant
linkage was obtained with the “low-
strigency” criteria, two PRL-secreting
adenoma cases in family 1 appeared to
represent phenocopies (Fig. 3A,
individuals A9 and A10). We, then, used
the identified founder haplotype in order
to detect additional haplotype carriers among sporadic patients from Northern Finland, but
we were not able to significantly narrow down the linked region. Because this chromosomal
region contained approximately 295 protein-coding and non-coding genes, an alternative
approach was needed to help simplify selection of candidate genes for mutation screening.
For this purpose, we opted to perform gene expression profiling, seeking for genes with
aberrant expression in the germline.
1.3 Gene expression profiling reveals AIP as the prime candidate gene for PAP
Gene expression profiles were generated from a total of 16 blood samples of patients and
obligatory carriers, as well as control individuals. A total of 23096 probe sets fulfilled the
analysis criteria at the whole-transcriptome level. Of these, 1735 probe sets reached a p-
value of ?0.05 in the t-test. The 50 probe sets most differentially expressed between
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patients/obligatory carriers versus controls are presented in Table S3 in the supplemental
material of publication I.
Next, we combined the genetic mapping with the gene expression array data, in order to
select positional candidate genes for mutation analyses, based on decreased expression. In
the linked region (11q12-11q13), 172 probe sets fulfilled the criteria; of these, 27 reached a p-
value of ?0.05. Two probe sets representing the AIP (aryl hydrocarbon receptor interacting
protein) gene occupied the first two positions, with p-values of 0.00026 and 0.00114 (Table S2
in the supplemental material of publication I). Removal of the two additional control
samples from a different project did not change the overall result, as AIP remained the best
candidate gene with the two probe sets at the 1st and  4th position (p=0.002 and 0.007,
respectively) (data not shown in Table S2). Therefore, AIP was chosen as the primary
positional candidate gene for mutation analysis.
1.4 Candidate gene mutation analysis establishes AIP as the predisposing gene
Apart from AIP, a second positional candidate gene, namely LGALS12 or galectin-12 (Yang
et al., 2001), was chosen; this was based on decreased LGALS12 expression and the previous
association of another member of the same protein family of lectins (LGALS3 or galectin-3)
to pituitary tumorigenesis (Riss et al., 2003). LGAL12 sequencing did not reveal germline
mutations in its coding region and exon-intron boundaries.
The AIP gene (NCBI NM_003977) resides on 11q13.3, spanning a region of 8 kb, and consists
of six exons transcribed in an mRNA transcript of 1212 bp that is translated to a 330 aa
protein. Direct genomic DNA sequencing in families 1 and 2 revealed an early stop codon
mutation, c.40C>T/Q14X, in the first exon of AIP. The mutation segregated perfectly with the
GH-secreting, GH/PRL-secreting, and three of five cases with the pure PRL-secreting
adenoma phenotype in both families. Q14X was absent in 209 population-matched healthy
controls. The number of affected cases in the giant pedigree (nine patients with the Q14X
mutation of a total of 11 affected cases) (Fig. 3A) is small compared to the number of
unaffected obligatory carriers identified (64 individuals at 50% risk) (Dr. Outi Vierimaa,
unpublished data); this indicates that AIP is a low penetrance tumor susceptibility gene.
Mutation screening of the Finnish population-based material of 45 acromegaly patients,
including four cases from families 1 and 2, revealed the Finnish founder mutation Q14X in
six patients and a splice-acceptor site (IVS3-1G>A) mutation in one patient. IVS3-1G>A was
not detected among 219 healthy, population-matched controls. cDNA analysis revealed that
IVS3-1G>A results in the recognition of a cryptic splice-acceptor site, 260 bp upstream of the
constitutive splice-acceptor site, at intron 3-exon 4 boundaries; this change leads to an
altered reading frame and, subsequently, to a premature termination codon. Overall, these
two AIP mutations accounted for 16% (7/45) of the population-based cases.
In this cohort, no statistically significant differences were observed between PAP (i.e. AIP
mutation-positive) patients (n=7) and mutation-negative (n=38) patients in terms of gender
or tumor size. Conversely, PAP patients were significantly younger at diagnosis (24.7±10.7
versus 43.6±11.9 years, p=0.0003). Six AIP mutation positive patients represented 40% of the
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15 patients that were younger than 35 years at diagnosis, indicating that young age at onset
is a useful indicator for identification of PAP cases.
In addition, Q14X was identified in two of ten (20%) unselected Finnish acromegaly patients
from Northern Finland, both diagnosed before the age of 35 years. This figure was very
close to the occurrence of AIP mutations among the 45 selected acromegaly cases.
To strengthen the association of AIP and PAP, it was relevant to identify additional
pathogenic mutations. For this purpose, we performed mutation screening in the index
cases of three families with two GH-secreting adenoma patients each; families originated
from Germany, Turkey, and Italy. We did not detect mutations in the German or Turkish
probands. On the contrary, a late stop codon mutation in exon 6 (c.910C>T/R304X) was
identified in the two Italian siblings; R304X was absent from 203 Caucasian controls and 52
healthy, population-matched controls. The Italian phenotype was very similar to that
observed in the Finnish PAP patients; both cases had been diagnosed at a very young age
(18 years) with acromegaly/gigantism and without visible evidence of dominant
transmission, which was compatible with incomplete penetrance.
Pituitary tumor samples were available from eight PAP cases with the Finnish founder
mutation (six familial and two sporadic). LOH analysis in these adenomas revealed the loss
of the wild type allele, compatible with the classical two-hit hypothesis for TSG inactivation.
Prior to gene identification, microsatellite marker-based LOH analysis, performed in six out
of these eight tumors, revealed LOH on the 11q12.2-q13.3 locus (unpublished data). No
tumor samples were available from the Italian siblings with the R304X mutation. These
findings, i.e. truncating mutations and biallelic inactivation of AIP in all tumors studied,
suggested that AIP is likely to act as a novel tumor suppressor gene.
2. Molecular diagnosis of PAP (II)
2.1 The contribution of AIP in heterogeneous pituitary adenoma patient cohorts of
different ethnic origins
Gene identification was facilitated given the genetically homogeneous Finnish population.
To gain insight into the clinical features of the condition, and to provide clues for molecular
identification of PAP, it was relevant to examine the contribution of AIP in other patient
materials and of different ethnic origin. For this purpose, the whole coding region and exon-
intron boundaries of AIP were screened in a total of 460 pituitary adenoma cases,
representing the various cohorts detailed in Subjects and Methods, section 1.2 and Table 7.
The analysis revealed nine presumably pathogenic AIP mutations and mutations were
identified in all cohorts studied: The Finnish founder mutation Q14X; two in-frame deletions
(c.66-71delAGGAGA/G23_E24del, and c.880-891delCTGGACCCAGCC/L294_A297del); one
bp insertion (c.824-825insA/H275Qfs) and one bp deletion (c.542delT/L181fs), both leading
to frameshift and premature stop codons; a splice-acceptor site substitution (IVS2-1G>C);
and three missense changes (c.878-879AG>GT/E293G, c.896C>T/A299V, and
c.911G>A/R304Q). All changes were absent in about 500 healthy control samples analyzed.
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The prevalence of AIP mutations varied between different cohorts and clinical settings: The
frequency was very low among apparently sporadic pituitary adenoma patients from
Poland (0.8%) and the USA (1.8%), recruited irrespectively of age at diagnosis or pituitary
tumor type; in addition, there were no significant findings among 71 unselected acromegaly
patients from Italy. On the other hand, in the selected cohorts of young acromegaly patients
from Finland and Germany, two mutations in each series accounted for 5.5% and 7.4%,
respectively.
Of interest is a missense variant in exon 1, R16H (c.47G>A), which was detected in one
Italian, one American, and three Polish pituitary adenoma patients, but also in one of 90
(1.1%) healthy control of German origin. In addition, two previously unreported silent
variants were found: c.696G>C/P232P in one Polish patient and c.906G>A/V302V in three
American patients. Even though neither of the silent variants was detected among more
than 200 Caucasian controls, they were not predicted to alter the transcript’s splicing
pattern, as tested in silico.
Finally, we opted to include in the analysis cases clinically suggestive of MEN1, but without
mutations in the menin gene, and found two mutations in a total of 91 (2.2%) Spanish and
Dutch cases of unexplained endocrine neoplasia. The findings are summarized in Table 1 of
the original publication (II) and also in Appendix Table 1; silent variants detected in study II
are excluded from the tables.
2.2 Clues into the phenotypic presentation of PAP patients
AIP mutations were enriched in patients diagnosed mainly with GH-secreting adenomas
(acromegaly) and at a young age, supporting the notion that AIP is a major GH-secreting
adenoma susceptibility gene. Despite the very young age at onset of the mutation carriers in
this study, family history of acromegaly became known for two PAP cases after mutation
identification: The father of the German patient with the G23_E24del also had acromegaly,
whereas his grandfather was suspected to have acromegaly (no biochemical tests available);
the Spanish patient with the L181fs mutation had two maternal uncles diagnosed with
acromegaly. Family history of endocrine neoplasia was not evident for the remaining PAP
cases. In addition, a patient with an ACTH-secreting tumor and Cushing’s disease was for
the first time identified to carry an AIP mutation (R304Q). These results pose a challenging
question regarding patient selection for possible genetic testing for PAP. Medical history of
the identified PAP patients was negative for tumor types other than pituitary adenomas.
2.3 Immunohistochemical detection of AIP protein
The identified germline AIP mutations in study I were truncating, associated with loss of the
wild-type allele in tumors; in other words, those pituitary tumors were null with respect to
the AIP protein. For this reason, in study II we examined the feasibility of AIP IHC, as a
molecular tool for possible PAP identification. By using a polyclonal AIP antibody, we
observed the subcellular localization of AIP in normal anterior pituitary tissue; the protein is
present in both the cytoplasm and the nucleus. Next, we examined 50 pituitary adenoma
specimens, of which 38 were mutation-negative and 12 were mutation-positive. The latter
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cohort consisted of nine tumors bearing the Finnish founder Q14X mutation, one tumor
bearing the Finnish IVS3-1G>A mutation, and two tumors from two US patients, one with
the IVS2-1G>C and the other with the H275Qfs. Most AIP-mutation negative adenomas
(36/38 or 95%) (i.e. AIP-proficient tumors) had preserved cytoplasmic and nuclear
immunoreaction, whereas most AIP-mutation positive adenomas (9/12 or 75%) (i.e. AIP-
deficient tumors) showed complete loss of both cytoplasmic and nuclear staining (Fisher’s
Exact test, p=4x10-6). Peripheral leukocytes captured in AIP-deficient tumor tissue sections
served as internal positive controls. Overall, AIP IHC showed 75% sensitivity and 95%
specificity for germline truncating mutations, indicating that it could be considered as
predictor for PAP.
3. The role of AIP in tumorigenesis of common cancers (III)
Following identification of AIP as a candidate TSG, it was relevant to examine its role in
tumorigenesis of common neoplasias, such as colorectal, breast, and prostate tumors. These
are the most prevalent cancers worldwide (Parkin et al., 2005). Moreover, acromegaly
patients have an increased risk for developing colonic polyps and, subsequently, colorectal
cancer. Circumstantial, but controversial, evidence supported that breast and prostate
hyperplasia and malignancy may arise more often in the context of acromegaly compared to
the general population (Jenkins, 2004). For this purpose, a total of 499 Finnish colorectal,
breast, and prostate tumor samples were utilized for somatic AIP mutation screening; no
presumably pathogenic mutations were identified.
Of interest was the previously mentioned missense variant R16H, detected in two of 373
colon cancer specimens, one being a microsatellite stable (MSS) and the other being a
microsatellite unstable (MSI) tumor. R16H was also present in the germline of both colon
cancer patients, but was absent in 209 healthy Finnish controls. No LOH was observed in the
tumors. The MSS patient had been diagnosed with cancer of the rectum at 64 years of age,
but due to unilateral breast enlargement, an occult pituitary adenoma was suspected; results
of a nuclear magnetic resonance examination undertaken in a private clinic were not
available and the patient is deceased. The MSI patient had been diagnosed with colon cancer
at the age of 81 years, but several other cancer patients with colorectal, cervical, and/or
carcinoid tumors clustered in the family. None of these patients’ samples were available for
further studies.
Apart from R16H, two silent changes (G12G and C238C), two rare polymorphisms (G23E
and 3’UTR +60G>C), a 5’UTR single bp substitution (-5G>C), and an intronic variant
(IVS3+15C>T) were also observed; the intronic and silent changes were not predicted to
affect the transcript’s splicing pattern, as tested in silico. The findings are summarized in
Table 1 of publication III.
4. The role of AIP in pediatric pituitary tumorigenesis (IV)
Pituitary adenomas occur rarely in childhood and adolescence. Such early disease onset may
in part be explained by genetic factors, since pediatric pituitary adenomas are observed in
the context of MEN1 and CNC (O’Brien et al., 1996; Stratakis et al., 2000; Brandi et al., 2001;
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Stratakis et al., 2001; Keil & Stratakis, 2008). In the adult sporadic pituitary adenoma patient
groups  from  studies  I  and  II,  germline AIP mutations had been identified among those
diagnosed mainly with GH-secreting tumors and at earlier age at onset than their non-
mutated sporadic counterparts. To gain more insight regarding the PAP phenotype, we
examined the prevalence of AIP mutations in a tailored pediatric series encompassing
different types of pituitary adenomas, in a unique population-based cohort of 36 unrelated,
sporadic patients from Italy: PRL-secreting adenomas accounted for 19 cases (53%), GH-
secreting adenomas for seven cases (19%), of which two cases were mixed GH/PRL-
secreting tumors, ACTH-secreting for three cases (8%), and NFPAs for seven cases (19%).
MEN1 had been excluded in all cases, after medical and biochemical investigation, and
MEN1 sequencing.
One heterozygous germline in-frame deletion of one amino acid (Y248del/c. 742-744delTAC)
was identified in a male adolescent giant patient, who was operated on for his GH-secreting
macroadenoma at the age of 19 years. IHC staining displayed expression of the mutant
protein, since LOH analysis of the tumor DNA clearly revealed that the wild type allele was
lost. The mutation was absent in 253 healthy Caucasian individuals, including 52
population-matched controls (Italy). The patient did not have a family history of pituitary
adenomas or any other endocrine-related disease. Mutation analysis among his first degree
relatives (both parents and the two siblings) revealed that the father was the carrier of the
mutant allele, which was transmitted to his three children. Except for the proband, all other
mutation carriers remain unaffected. Detailed clinical examination and biochemical
evaluation (IGF-I) of the unaffected carriers were normal, but other endocrine and imaging
studies had not been performed at the time of the preparation of the present work. The brief
medical history obtained from the relatives of the paternal side was negative for endocrine
disease, but none has been genetically tested nor clinically examined for pituitary lesions.
Overall, this adolescent PAP patient accounted for 1/36 or 2.8% of pediatric pituitary
adenomas and for 1/7 or 14.3% of all GH-secreting tumors in the series.
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DISCUSSION
1. AIP is a novel, low penetrance tumor susceptibility gene that causes
Pituitary Adenoma Predisposition (PAP) (I)
1.1 Insights into the hereditary predisposition to pituitary adenoma development
(I)
The occurrence of multiple cases of pituitary tumors, and in particular GH-secreting
adenomas, among first-degree relatives within single families is very uncommon (Soares &
Frohman, 2005). Acromegaly is rare in the general population, with merely three to four
new cases per million per year (Alexander et al., 1980; Bengtsson et al., 1988; Kauppinen-
Makelin et al., 2005). Therefore, the occurrence of pituitary adenomas in Finnish familial
settings, which did not depict the MEN1 and CNC syndromes, prompted consideration of
an inherited disorder. Efforts by other groups had previously concentrated on the
identification of a TSG predisposing to acromegaly (IFS); this gene was thought to reside on
11q13, very close to, yet distinct from, MEN1 (Yamada et al., 1997; Gadelha et al., 1999;
Gadelha et al., 2000).
The identification of three familial pituitary adenoma clusters in Northern Finland in 2004,
two of which were linked by genealogy to a giant pedigree, led to the hypothesis that a
previously uncharacterized form of low penetrance pituitary adenoma predisposition (PAP)
would contribute to the disease burden in the area. These families had been excluded from
MEN1 and CNC, due to the lack of clinical, biochemical, and genetic (in the case of MEN1)
evidence, but also due to the unique low penetrance of the PAP phenotype. Family 1 was
excluded from the IFS phenotype, since several affected members had been diagnosed with
a PRL-secreting adenoma.
We named the condition caused by germline AIP mutations as “Pituitary Adenoma
Predisposition” (PAP). Because susceptibility to pituitary adenomas is likely to be
genetically heterogeneous, and each defective gene might confer to particular clinical
features, it was useful that the condition attributed to AIP had a name. Thus, PAP refers to a
person with an AIP mutation, independent of the affection status; predisposition exists also
for the unaffected germline mutation carriers. Germline mutations in tumor susceptibility
genes cause tumor predisposition, not tumors per se (Vogelstein & Kinzler, 2004), since
additional genetic changes are needed to convert a predisposed cell to a neoplastic one.
The approach for PAP gene identification is summarized as follows (Fig. 5): First,
identification of the putative disease predisposition locus segregating in family 1, through
genome-wide SNP chip-based genotyping and linkage analysis; second, characterization of
the linked haplotype with 36 microsatellite and SNP markers; third, utilization of the
founder haplotype for detection of additional haplotype carriers among sporadic patients
from Northern Finland, in an effort to further narrow down the disease locus; fourth,
generation of gene expression profiles from the blood samples of individuals segregating the
disease-associated haplotype versus controls; and fifth, the combination of genetic mapping
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data and whole-transcriptome expression array data to pinpoint positional candidate genes
for germline mutation analyses.
The successful identification of AIP as the PAP gene is owing to the innovative approach of
combining traditional gene mapping methods with modern chip-based technologies.
Despite the large size of family 1, informative meiotic recombinations that would help us
restrict the predisposition locus below ~7 Mb were still lacking. In genetically homogeneous
populations, such as the Finnish, haplotypes spanning as much as 10 cM have been
observed to surround ancestral founder mutations with strong LD (de la Chapelle, 1993), as
in the identification of the HNPCC predisposition loci (Nystrom-Lahti et al., 1994).
Luccio-Camelo et al. (2004) mapped the locus for familial acromegaly (IFS) to 10 Mb on
11q13; in this family, an 18-year old member had a critical recombinant chromosome at
11q13, but remained unaffected. If this person eventually developed acromegaly, it would
have helped narrow the IFS candidate region from 10 Mb to 3.9 Mb (including the AIP, but
not the MEN1, locus) (Luccio-Camelo et al., 2004). This case highlights that the quest for
meiotic  recombinations  in  such  rare  pedigrees,  in  concert  with  the  slowly  progressing
acromegaly phenotype, may had been a time-consuming approach for susceptibility gene
identification, if based solely on linkage analysis and screening of potentially attractive
positional candidate genes.
Figure 5. Flowchart describing the
strategy for PAP gene identification
(reproduced from Vahteristo et al., 2007
with the copyright holder’s permission).
With the advent of gene expression
profiling, an alternative approach to
candidate gene identification was
made possible. Here, we tested for
aberrant gene expression in the
germline of pituitary adenoma
patients/obligatory carriers versus
healthy controls. In our gene
expression profiling experiments, we
were seeking for genes that would
be underexpressed, based on the
literature supporting the loss of a
putative TSG. The success of this
experiment was due to two
determining factors: Firstly, the fact
that human AIP is rather
ubiquitously expressed (SymAtlas, 2008 at http://symatlas.gnf.org; unpublished
observations); if its expression had been pituitary-specific, or restricted in endocrine tissues,
it would have been impossible to detect aberrant expression from blood derived mRNA.
Secondly, gene underexpression would require that the predisposing mutations are severe
enough to cause loss of the expression of the mutant allele, such as: a) (early) nonsense
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mutations and small insertions or deletions that cause frameshift, all leading to premature
stop codons and degradation of the transcripts by NMD, b) promoter aberrations impairing
gene transcription, or c) copy number variations, such as partial or whole-gene deletions.
Indeed, the germline mutation analysis revealed a very early termination codon, in exon 1 of
AIP (Q14X), segregating with the GH-, mixed GH/PRL, and partially with the PRL-secreting
adenoma phenotypes, in families 1 and 2.
The power of this approach, combining peripheral blood genome and transcriptome (BGT)
analysis (Vahteristo et al., 2007), had been previously tested for two other site-specific tumor
susceptibility genes, MLH1 and fumarase (FH), causing HNPCC and HLRCC respectively; in
both cases, genes displayed significantly reduced expression in mutation carriers
(unpublished data). More recently, Vahteristo et al. (2007) reported the success of the
method in identifying the genetic etiology of autosomal recessive xeroderma pigmentosum
type E (XPE) in a patient who had negative results in tests routinely undertaken in XP
diagnostics. The striking feature of this study was that only the samples from the patient
and his healthy carrier parents, versus healthy controls, suffized to reveal the genetic defect
in this skin cancer case. Thus, this approach may also assist in elucidating genetic defects in
disorders with high locus heterogeneity.
The low PAP penetrance contrasts with the two major familial endocrine-related tumor
syndromes MEN1 and CNC where penetrance is nearly complete (Bassett et al., 1998;
Stratakis et al., 2001). In fact, only one affected sibling pair was identified among the Finnish
patients. Low penetrance alleles may be much more frequent in the general population than
high penetrance susceptibility alleles that are typically uncommon. It may be that
environmental factors, additional random somatic mutations in the pituitary, or genetic –
perhaps pituitary-specific – modifiers affect the clinical expression of PAP. Despite the
plausibility of these hypotheses, the issue of the true PAP penetrance in Finland remains the
subject of study. Clearly, much larger pedigrees and thorough medical investigation is
needed.
Here, it is interesting to note that a subcluster from the Finnish family 1, with two female
prolactinoma cases (daughter and a maternal sister) did not harbor an AIP mutation, as
analyzed by direct sequencing (Fig 3A, A9 and A10). Since prolactinomas are the most
common type of pituitary adenomas (40-45%) and occur more frequently in women (Arafah
& Nasrallah, 2001), these cases may represent disease phenocopies. Therefore, the
occurrence of two sporadic cases within the same family, independent of AIP
predisposition, is possible.
In a subsequent report of a large collection of FIPA families, Daly et al. (2007b) found that
15% of the families screened for germline AIP mutations were positive; among these, the IFS
families represented 50% of all IFS families recruited in the study. It is important to
highlight that a large number of candidate families screened for AIP mutations were
negative (Table 8). It may be that these patients carry different types of mutations, not
detected by conventional sequencing, such as large genomic deletions or other
rearrangements. Very recently, 21 familial pituitary adenoma index cases, previously tested
negative for intragenic germline AIP mutations, were analysed for AIP copy number
changes by the Multiplex Ligation-dependent Probe Amplification (MLPA) assay; two of 21
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(9.5%) families were found to carry large genomic deletions, presumably occurring due to
Alu-mediated unequal homologous recombination (Georgitsi et al., 2008). Nevertheless, the
lack of intragenic AIP mutations in pedigrees with strong familiality for pituitary adenomas
(Daly et al., 2007b) makes it likely that other genes, yet to be identified, may confer genetic
susceptibility to pituitary tumorigenesis.
2. Molecular diagnosis of PAP
2.1 Germline AIP mutations in pituitary adenoma patients of various ethnic
origins and clinical settings (II)
In order to gain more insight regarding the spectrum of the PAP phenotype, a large cohort
of pituitary adenoma patients from genetically heterogeneous populations from Europe and
the USA was screened for germline AIP mutations. Interestingly, presumably pathogenic
mutations were identified in all populations and clinical settings studied, albeit with low
frequencies. The highest mutation frequencies (5.5% and 7.5%) were observed among
patients with a very young age at onset, diagnosed with acromegaly/gigantism. The mean
age at diagnosis among all AIP mutation carriers was 23.8 years, supporting the findings of
study I that PAP is associated with young age at onset (Karhu & Aaltonen, 2007). In some
young PAP patients a family history of acromegaly was unravelled after mutation detection,
but, overall, positive family history was a weak indicator of PAP, supporting the notion of a
low penetrance condition. The contribution of de novo mutations  in  PAP  remains  to  be
examined, but it was not possible in the context of study II. These findings indicate that due
to the low mutation frequencies, routine molecular screening is not currently justified for all
pituitary adenoma patients, as discussed below (see section 5).
The clinical relevance of the three missense variants observed in this study (E293G, A299V,
R304Q) remains undetermined and functional studies are necessary to clearly establish a
connection to the disease; yet, the absence of these variants in the hundreds of healthy
controls screened, as well as the conservation of the AIP amino acid sequence among several
species, argue for an association with the condition. In addition, these missense mutations
occur on exon 6, which codes for the C-terminal part of the AIP protein that harbors crucial
protein-protein interaction domains, as detailed later (see section 6); thus, a potential
pathogenic effect cannot be excluded at present.
The R16H variant detected in four sporadic pituitary adenoma patients from study II, has
also been found in a French FIPA family (Daly et al., 2007b), in two French sporadic
acromegaly patients (Cazabat et al., 2007), in two German sporadic NFPA patients
(Buchbinder et al., 2008), in a young Bulgarian sporadic PRL-secreting adenoma case
(Yaneva et al., 2008), in one of two affected cases of an Italian non-medullary thyroid cancer
family (Raitila et al., submitted manuscript), in two Finnish colorectal cancer patients (study
III), as well as in three healthy controls (study II; Cazabat et al., 2007). The following lines of
evidence now argue in favor of R16H being a rare polymorphism: Firstly, its presence
among healthy individuals; secondly, its presence among different pituitary adenoma types
studied, as well as in thyroid and colorectal cancer patients without pituitary adenomas;
thirdly, the lack of LOH in all R16H-positive tumors examined, and lastly the possible lack
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of an effect on splicing as tested in silico. On the other hand, because of the low disease
penetrance observed in PAP, at this point we cannot exclude any pathogenic association.
2.2 The PAP phenotype
By reviewing the PAP cases reported in study II, it emerges that PAP patients are typically
diagnosed at a young age, have mainly GH-secreting adenomas and lack a strong family
history of pituitary adenomas or other endocrine disease. Yet, other pituitary adenoma types
in PAP cannot be excluded, since in the overall literature AIP mutations have been detected
among mixed GH/PRL and PRL-secreting adenoma patients (study I; Daly et al., 2007b;
Raitila et al., 2007; Naves et al., 2007; Leontiou et al., 2008), NFPA patients (Daly et al., 2007b;
Leontiou et al., 2008; Georgitsi et al., 2008), and two ACTH-secreting adenoma (Cushing’s
disease) cases (study II; Beckers et al., 2008). It has also become evident that the same AIP
mutation can be associated with a variable pituitary tumor phenotype, even within the same
family: For instance, Q14X carriers in the Finnish family 1 had GH-,PRL-, or mixed GH/PRL-
secreting adenomas (study I), E174fs carriers in a Brazilian family had GH- and mixed
GH/PRL-secreting adenomas (Naves et al., 2007), R304X carriers in several families had
mostly GH-secreting, but also PRL- and mixed GH/PRL-secreting adenomas (Daly et al.,
2007b; Leontiou et al., 2008), whereas among the two siblings with the in-frame Ex2del, one
had been diagnosed with NFPA and the other with a GH-secreting adenoma (Georgitsi et
al., 2008) (Appendix Table 1). The lack of phenotype-genotype correlation among patients
with the same mutations has been observed in other hereditary tumor syndromes (reviewed
in Kinzler & Vogelstein, 1996; Vierimaa et al., 2007) and points towards the involvement of
additional genetic/epigenetic factors or modifier genes (Antonarakis & Beckmann, 2006).
Whether AIP mutations are associated with larger, and perhaps more aggressive, pituitary
tumors warrants further investigation. In the analysis of sporadic PAP cases in study I no
significant difference was observed in the tumor size between mutation-positive (n=7) and
mutation-negative (n=38) cases. Contrary, Daly et al. (2007b) observed that tumor diameter
was significantly larger among familial AIP mutation-positive (n=26) versus AIP mutation-
negative cases (n=130) (p=0.0005). Perhaps our numbers in study I were small and could not
reach statistical significance.
To date, the only tumors that have been found to unambiguously associate with AIP
mutations are pituitary adenomas, contrasted with MEN1 and CNC, where several other
tumor types are among the typical manifestations. Interestingly, several cases of thyroid
disorders, including nodular goitres, follicular adenomas, and follicular and papillary
thyroid carcinomas, have been observed in Finnish AIP mutation-positive families (Drs Outi
Vierimaa and Pasi Salmela, unpublished observations). Whether there is an association
between such a spectrum of thyroid disorders and predisposition caused by AIP remains
unclear; the identification of more PAP families presenting with thyroid disease is clearly
needed to address this issue. In a recent study, no evidence for such an association was
found (Raitila et al., submitted manuscript). Thyroid abnormalities, such as goitre, have been
detected among acromegalic patients (Gasperi et al., 2002; Tita et al., 2005; Kurimoto et al.,
2008), but thyroid cancer is more rare, despite being the most common endocrine
malignancy (Grubbs et al., 2008). The occurence of such abnormalities in acromegaly patients
may be attributed to the prolonged thyroid tissue exposure to high serum IGF-I (Tita et al.,
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2005; Siegel & Tomer, 2005). Moreover, adrenal carcinoma and lipomas have presented with
pituitary adenomas in AIP mutation-positive families (Leontiou et al., 2008; Toledo et al.,
2008a). What is of particular interest here is that the GH-secreting adenoma and the adrenal
carcinoma tissues of two patients reported by Leontiou et al. (2008) and Toledo et al. (2008b)
showed LOH. Because adrenal carcinomas often exhibit chromosomal instability (LOH) in
11q13 (Leontiou et al., 2008), the analysis of more adrenal gland tumors in the context of PAP
is now warranted.
2.3 The potential of AIP immunohistochemistry as a diagnostic tool (II)
In study II, AIP IHC staining in 50 pituitary adenoma specimens proved to be a useful
predictor for PAP, with 75% sensitivity and 95% specificity for germline truncating
mutations. In two cases that were negative for an AIP mutation, negative staining was
observed; this may be attributed to technical reasons, or to the presence of a different type of
germline mutation that remains undetected by conventional sequencing (i.e. a large genomic
deletion). Three tumors were positive for an AIP mutation (two with the Q14X and one with
the IVS3-1G>A), but also positive for AIP staining. In the case of the Q14X positive tumors
LOH had been detected previously, thus unspecific staining cannot be ruled out. LOH
analysis for IVS3-1G>A was equivocal; a plausible explanation could be that the “second
hit” is not loss of the wild type allele, but a missense-type of mutation or a small in-frame
deletion that results in non-functional, yet stable and immunoreactive, protein. However,
with the exception of half of exon 3 that repeatedly failed to amplify, the rest of the coding
AIP sequence was negative for a second point mutation.
Here, it should be noted that IHC detection of mutant AIP largely depends on the type of
germline mutation and second hit mutation in the tumor tissue, but also on the antibody
used. In study II, a polyclonal mouse antibody was utilized as optimal at the time. IHC
staining showed 75% sensitivity for germline truncating AIP mutations and in these cases
tumors clearly exhibited LOH as the second hit. Others found partial immunoreactivity in a
germline truncating mutation-positive pituitary tumor, by using a different monoclonal
antibody against human AIP (Naves et al., 2007). In this study, cytoplasmic AIP staining was
observed in approximately 30% of tumor cells when compared to adjacent normal pituitary
tissue; results could not be correlated to LOH analysis, because the latter was equivocal. In
another study, AIP immunostaining in adenomas from two AIP-mutation positive families,
bearing the R304X and the in-frame duplication c.794-823dup30 (A274_H275ins10), was
positive (Leontiou et al., 2008). Yet, this may not be completely unexpected, since R304X and
A274_H275ins10 occur late in the AIP sequence  (both  in  exon  6)  and  may  allow  for  the
expression of a stable and immunoreactive, yet possibly dysfunctional, protein.
2.4 Overview of the molecular genetics of AIP
Since identification of the AIP gene, tens of germline mutations have been found in pituitary
adenoma patients of various ethnic origins, either in familial or sporadic settings
(summarized in Tables 8, 9, and Appendix Table 1). The mutation spectrum includes single-
point mutations (missense or nonsense), small insertions and deletions, in-frame deletions
and one in-frame duplication, splice-site mutations, promoter changes, and even large
genomic deletions (Fig. 6, Appendix Table 1, Appendix Fig. 1). These pathogenic changes
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are predicted to either hinder the expression of normal AIP protein, or result in altered
protein structure and/or protein function. Interestingly, the majority of germline AIP
mutations are truncating, supporting a tumor suppressive role. This is reminiscent of the
other two endocrine-related tumor susceptibility TSGs, MEN1 and PRKAR1A, with the vast
majority of reported mutations being truncating (Stratakis et al., 2001; Marx, 2005; The
Human Gene Mutation Database 2008 at www.hgmd.org).
Mutations appear to be scattered quite evenly in the coding region of AIP, despite a notable,
yet possibly coincidental, clustering of missense changes at the 3’ end (exons 5 and 6),
between codons 238-304. These missense mutations occur within the regions coding for the
crucial interaction domains of AIP, the tetratricopeptide (TPR) repeats (Fig. 6).  Mutational
analyses of the TPR domains, before anything was known about the implication of the gene
in pituitary tumorigenesis, showed how essential they are for the interactions of AIP with its
cellular partners (Bell & Poland, 2000; Melville et al., 2000; Bolger et al., 2003).
Figure 6. Schematic representation of the AIP transcript with all germline mutations reported in the
literature by June 2008 (see also Appendix Table 1). The numbers in parentheses indicate the number
of families with the same mutation. Numbers 1-6 denote the six exons of the transcript, separated by
vertical  dashed  lines.  The  grey-lined  boxes  represent  the  5’  and  3’  UTRs.  The  dark  grey  box  partly
overlying exon 1 and almost completely exon 2 designates the FKBP domain. The smaller dark grey
boxes overlying parts of exons 4, 5, and 6 represent the three TPR repeats (see also Fig. 7).
It is not currently clear whether mutations causing NMD (i.e. early stop codons and
frameshift mutations causing premature stop codons) cause a less severe phenotype than
smaller intragenic mutations that possibly escape transcript degradation (i.e. missense
mutations, small in-frame insertions or deletions, including single exon deletions). In the
future, detailed clinical and biochemical examinations of patients carrying these different
types of mutations may help reveal information on disease penetrance and severity,
response to drug therapy, or tumor relapse.
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Table 8. Germline AIP mutation analysis conducted in familial pituitary adenoma cases as
reported in the literature by June 2008.
Reference Total No
of analyzed
families
Total No of
mutation-
positive families
No of kindreds
with familial
acromegaly in
the series
No of mutation-
positive kindreds
with familial
acromegaly in the
series
Study I 5 3 4 2/4 (50%)
Daly et al., 2007b 73 10 16 8/16 (50%)
Iwata et al., 2007 1 1 1 1/1 (100%)
Toledo et al., 2007 1 1 1 1/1 (100%)
Raverot et al., 2007 1 0 0 0
Leontiou et al., 2008 26 9 21 9/21 (43%)
Georgitsi et al., 2008 23* 2 7 1/7 (14%)
Fajardo Montanana et al., 2008 1 0 1 0/1
Yaneva et al., 2008 2 0 0 0
Total 133 26 51 22/51 (43%)
No, number
* 21/23 probands were successfully analyzed by the MLPA assay.
Table 9. AIP mutation analysis carried out in sporadic pituitary adenoma cases as reported
in the literature by June 2008§.
Reference Total No of
analyzed
cases
Total No of
mutation-positive
cases
No of cases
diagnosed with
GH-secreting
adenoma in the
series
No of mutation-
positive cases with
GH-secreting
adenoma in the
series
Germline screening
Study I 41 5 41 5/41 (12%)
Study II 433 7/433 (1.6%) 176 6/176 (3.4%)
Yu et al., 2006* 63 0/63 35 0/35
Barlier et al., 2007 107 0/107 26 0/26
Cazabat et al., 2007 154 5/154 (3%) 154 5/154 (3%)
DiGiovanni et al., 2007** 78 0/78 62 0/62
Leontiou et al., 2008 37 0/37 37 0/37
Study IV 36 1/36 (2.8%) 7 1/7 (14%)
Yaneva et al., 2008 8 1/8 (12.5%) 5 1/5 (20%)
Somatic screening Total No of
tumors
analyzed
Total No of
mutation-positive
tumors
No of GH-
secreting tumors in
the series
No of mutation-
positive GH-
secreting tumors in
the series
Study I 10 0 10 0
Study II 27 2/27 (7.4%) 27 2/27 (7.4%)
Iwata et al., 2007 40 0/40 40 0/40
Barlier et al., 2007 41 2/41 (5%) 23 2/23 (8.7%)
Raitila et al., 2007 32 2/32 (6%) 23 0/23
Leontiou et al., 2008 48 0 NA 0
No, number; NA, information not available
§ Cohorts are presented irrespectively of the selection criteria based on which they were published.
* AIP mutation analysis was incomplete, performed only for exons 1, 4, and 6.
** AIP mutation analysis was incomplete, performed only for exons 1, 4, 5 and 6.
All germline AIP mutations reported in the literature to date have been seen in
heterozygosity, which implies that homozygous germline AIP mutations and AIP deficiency
are most likely not compatible with life. This is in agreement with the recent observations
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that Aip-/- mice  die in utero at  various  time  points,  but  already  around  E10,  due  to
cardiovascular defects, suggesting an essential role for Aip protein in cardiac development
(Lin et al., 2007). In addition, homozygous hypomorphic Aip mice are born without cardiac
defects; instead, they show defective closure of the hepatovascular shunt, called ductus
venosus, and have decreased liver weight due to reduced blood supply (Lin et al., 2008). Aip
is expressed early in embryonic development, as early as E9.5, well before some of its
known interaction partners (Lin et al., 2007). These observations speak for a broader role of
Aip in mammalial biology. It remains to be seen whether human AIP has yet unidentified,
and perhaps pituitary-specific, interaction partners and, thus, additional biological
functions.
3. AIP does not appear to contribute to tumorigenesis of common
cancers (III)
The biallelic inactivation of AIP, based on LOH and IHC data obtained from pituitary
tumors (studies I, II; Raitila et al., 2007), in concert with recent in vitro functional data on the
reduced ability of mutant AIP to inhibit cell proliferation (Leontiou et al., 2008), argue in
favor of a tumor suppressive role. Following gene identification, it was relevant to examine
whether AIP is involved in the tumorigenesis of other tissues. For this purpose, we
performed somatic mutation analysis in a total of 499 colorectal, breast, and prostate tumor
samples. Apart from being very prevalent worldwide, these tumors – colorectal neoplasia in
particular – have been previously associated with acromegaly (Jenkins, 2004).
The only interesting variant observed was the missense change R16H, detected in one MSS
and one MSI colorectal tumor without LOH, as well as in the corresponding normal tissues.
The possibility of an occult pituitary GH- or PRL-secreting adenoma in the MSS patient (no
data on serum PRL levels available) could have promoted the breast enlargement and
colorectal cancer, but the patient passed away and no further studies were performed. The
presence of a carcinoid tumor in the brother of the MSI patient with the R16H was
interesting, since carcinoids are features of MEN1. However, the lack of material for
segregation analysis in this family hindered further investigation of a possible association.
No other presumably pathogenic mutations were detected, indicating lack of evidence for
an immediate role of AIP in the initiation or progression of these tumor types. Recently,
Sjoblom et  al. (2006) and Wood et al. (2007) published the genomic landscapes of human
breast and colorectal cancers in two massive screening works; AIP was not found among the
genes that are somatically mutated at significant frequency, adding support to the notion
that AIP is unlikely to be involved in these two cancer types (Sjoblom et al., 2006; Wood et al.,
2007).
These findings did not rule out the possibility that AIP could be somatically mutated in
other tumor types, perhaps more closely related to endocrine neoplasia. To address this
issue, sporadic endocrine-related tumors (total n=111; 32 pituitary adenomas and 79 other
endocrine tumors) were analyzed by Raitila et al. (2007); somatic AIP mutations appeared to
be very rare in this setting as well. The only finding was the Finnish founder mutation
Q14X, identified in two PRL-secreting adenomas showing LOH. Both patients were
Genetic Basis of Pituitary Adenoma Predisposition
60
diagnosed at the age of 35 years. The first patient did not have a family history of endocrine
tumors, whereas relevant information was not available from the second. These results were
in accordance with previous observations regarding the early age of onset and the lack of
strong family history among PAP patients (study I, II). In addition, this study further
confirmed that PRL-secreting adenomas are part of the PAP phenotype.
Since gene identification, other groups have sought for somatic AIP mutations in sporadic
pituitary adenomas of various types (Table 9), with mostly negative results (Iwata et al.,
2007; Barlier et al., 2007; Leontiou et al., 2008). Interestingly, the other two major endocrine
tumor susceptibility genes, MEN1 and PRKAR1A, are only rarely found somatically mutated
in sporadic pituitary adenomas (reviewed in Thakker, 1998; Sandrini et al., 2002; Kaltsas et
al., 2002; Yamasaki et al., 2003) or other sporadic endocrine tumors (Zhuang et al., 1997b;
Toliat et al., 1997; Heppner et al., 1997; Vortmeyer et al., 1998). Sporadic pituitary tumors
have been also screened for somatic CDKN1B mutations, with negative results (Takeuchi et
al., 1998; Dahia et al., 1998; Ozawa et al., 2007).
Recent data show that other mechanisms, such as epigenetic inactivation of TSGs, may also
account for a subset of the sporadic form of the disease (Esteller et al., 2000). Gene silencing
caused by epigenetic mechanisms, through for instance promoter hypermethylation, is an
event encountered in as many as 50% of TSGs in sporadic tumors (Jones & Baylin, 2002),
such as BRCA1 in  sporadic  breast  tumors, PRB in sporadic retinoblastomas, and MLH1 in
sporadic colorectal and endometrial cancers (reviewed in Weinberg, 2007). Epigenetic
silencing of AIP has not been reported in pituitary adenomas thus far, but little time has
elapsed since gene identification and relevant studies may be under way.
4. Pediatric GH-secreting tumors may arise due to AIP mutations (IV)
The occurrence of pituitary tumors among children and adolescent patients is very rare.
Approximately 2-6% of all surgically treated pituitary adenomas occur in young patients;
PRL- and ACTH-secreting adenomas are the most common types. It is conceivable that such
early disease onset may be in part explained by an underlying genetic predisposition, as
observed in very young MEN1 and CNC patients with pituitary adenomas (O’Brien et al.,
1996; Stratakis et al., 2000; Brandi et al., 2001; Stratakis et al., 2001; Keil & Stratakis, 2008). In
order to examine whether PAP could partly explain the pediatric disease onset, and given
the typically young age at onset among the adult PAP patients, we obtained a pediatric
series encompassing all pituitary adenoma types encountered at this age group.
Among 36 sporadic pediatric cases analyzed for germline AIP mutations, one male patient
was found to carry the in-frame deletion Y248del. This patient was operated on at the age of
19 years for a GH-secreting adenoma causing gigantism during adolescence. Loss of the
wild type allele on tumor DNA level was clearly observed; thus, the positive IHC staining
was indicative of the retention of the mutant protein, assuming that the presumably
defective mRNA escaped degradation. It may be that non-functional, yet immunoreactive,
protein is present in these GH-secreting adenoma cells. It is not straightforward whether
Y248del compromises the normal AIP function in the pituitary tissue. Several reasons argue
in favor of a presumably pathogenic effect of the mutation on the protein’s normal function:
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Firstly, Y248del occurs on the second of three TPR repeats, which mediate the crucial
interactions between AIP and its cytoplasmic partners. Secondly, tyrosine 248 is highly
conserved among several species. Thirdly, the change was not observed in 253 healthy
individuals, including 52 population-matched controls, thus providing little evidence for
Y248del being a rare polymorphism among the Italian population.
Interestingly, all of the patient’s first-degree relatives that are mutation-carriers (the father
and the two other siblings) remain to date unaffected and no family history of endocrine
disease has been reported. Clinical investigation and genetic testing among the paternal
relatives would help clarify whether this is a truly sporadic case or yet another family with
very low disease penetrance.
Data from study IV showed that AIP mutations are an important factor underlying GH-
secreting adenomas (1/7 or 14.3%) in children and adolescents. Therefore, it was relevant to
examine the prevalence of AIP mutations among young (?25 years) GH-secreting adenoma
patients, in order to also gain insight into a patient group that could benefit from genetic
counseling and genetic testing. Along these lines, relevant data were reviewed from our
previous reports and the work of others (studies I, II, and Iwata et al., 2007). It was
concluded that PAP patients account for 40% of patients diagnosed at ?25 years, in
comparison to 1.6% of patients diagnosed after 25 years (p=5x10-9) (Table 3 of publication
IV). If the cases from the Finnish population, known to harbor a founder mutation, were
excluded, then young (?25 years) PAP patients would account for 14.3%, in comparison to
0.5% of cases diagnosed >25 years (p=0.013) (Table 4 of publication IV). These figures are
very similar to the numbers reported by Cazabat et al. (2007), where, in a similar approach,
AIP mutation-positive patients accounted for 12.5% of patients <30 years at diagnosis versus
0.8% of patients diagnosed at >30 years of age.
Obviously, study IV was conducted in a cohort of pediatric patients of a single ethnic origin,
and more studies are needed to further address the role of AIP in pediatric pituitary
tumorigenesis. Yet, the size of the cohort, the detailed clinical documentation, and the fact
that most pituitary adenoma types are represented despite the extreme rarity of the disease
in children and adolescents, add further value to these findings. After study IV was
accepted for publication, a cohort consisting of seven sporadic giants of various ethnic
origins (Australia=1, USA=1, UK=3, Brazil=2) with childhood-onset GH-secreting pituitary
adenomas was published; no germline AIP mutations were detected (Leontiou et al., 2008).
On the contrary, a novel AIP mutation (K103R) was identified in one Cushing’s disease
patient from a cohort of 76 pediatric-onset cases, and three novel mutations (Q307fs, P114fs,
and K241X) were detected in three patients of a series of 11 pediatric-onset pituitary
adenoma cases with syndromic features (Beckers et al., 2008). These results add further
support to the notion that mutant AIP predisposes to pediatric-onset pituitary
tumorigenesis.
5. Implications for genetic counseling and follow-up in PAP
Whether genetic testing of AIP could facilitate identification of at-risk individuals has
attracted interest and controversy. Years of research may be still required before AIP
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mutation screening has an impact on the patients’ clinical management and treatment. Yet,
implementation of predictive genetic testing for the relatives of mutation-positive patients
can identify asymptomatic mutation carriers and result in early tumor detection (Cazabat et
al., 2007). On the other hand, predictive testing raises psychological and ethical
considerations, which may be of great concern in the case of low penetrance conditions, such
as PAP.
It has been proposed that genetic screening of AIP is rather premature, given the rarity of
the familial pituitary adenomas, the small size of the affected families, and the infrequent
occurrence of AIP mutations (Melmed, 2007; Melmed, 2008). Instead, biochemical screening
tests (i.e. serum IGF-I, GH, and PRL measurements), should be preferred in the clinic as the
primary mode of action for monitoring at-risk individuals, since they are universally
available, easily affordable, accurate, and superior to imaging screening (Melmed, 2008).
Indeed, it is true that genetic counseling demands resources, DNA testing typically requires
prior genetic counseling, and DNA sequencing might still be more costly that biochemical
tests. However, it seems futile to offer lifelong biochemical screening to non-carriers; on the
contrary, predictive genetic testing can help identify the family branches and individuals
who segregate an AIP mutation and truly are at an increased risk. Therefore, biochemical
and imaging screening, following AIP mutation testing, could be focused on the actual
carriers,  which  is  clearly  superior  to  biochemical  screening  alone.  In  a  similar  approach,
MEN1-negative individuals have been spared regular biochemical evaluations, whereas
biochemical and radiological monitoring has been provided to MEN1 mutation carriers
only, with beneficial effects on the disease morbidity and long-term outcome (Bassett et al.,
1998; Brandi et al., 2001; Klein et al., 2005; Pieterman et al., 2008).
No concensus guidelines exist yet regarding the criteria that should be fulfilled to justify AIP
genetic testing. Perhaps the widespread use of genetic screening in unselected patients with
sporadic pituitary adenomas is not currently warranted. However, genetic testing could
focus on a targeted group, such as the familial acromegaly cases with young age at onset
and their relatives. Among all pedigrees screened for AIP mutations thus far (n=133),
familial acromegaly kindreds account for about one third (n=51), of which almost half have
PAP (22/51 or 43%) (Table 8). This highlights the fact that AIP remains the major known GH-
secreting adenoma susceptibility gene outside the context of MEN1, CNC, or MAS. Lastly,
diagnostic genetic testing could be considered for the young patients with aggressive
pituitary tumors (Beckers & Daly, 2007).
Undoubtably, in order to provide informative counseling about PAP to patients and their
family members, there is the primary need to unravel its penetrance. Because PAP is a low
penetrance condition, it is expected that most mutation carriers are healthy. Among the
giant Finnish pedigree (study I), 64 individuals at 50% risk have been identified (Dr. Outi
Vierimaa, unpublished data); however, the estimated disease penetrance has not been
established yet. In such families, detailed clinical and biochemical investigations of
mutation-carriers are expected to contribute significantly to defining the disease penetrance,
but this has proven a time-consuming effort.
Direct DNA sequencing and MLPA analysis unambiguously remain the most appropriate
tools for PAP indetification on genomic level. One consideration may be, though, that
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genetic testing, as the primary molecular tool for diagnosis, remains a costly procedure that
requires genetic counseling and resources. On the other hand, surgically removed pituitary
adenomas are routinely examined by IHC for tumor classification and diagnostic purposes;
in United States alone, thousands of paraffin-embedded GH-secreting adenoma samples are
available for prescreening of PAP by IHC, pending patients’ consent. For this reason, in
study II we proposed that, in addition to signs such as young age at onset or positive family
history, and with the appropriate methodological improvements (e.g. new specific
antibodies), negative AIP IHC in pituitary adenomas may serve as a useful tool for PAP
identification in the future. This approach would be similar to tumor-based approaches now
in routine use in the diagnosis of hereditary colon cancer (Hampel et al., 2005).
6. The AIP protein and its cellular functions
6.1 Features of the AIP protein
Originally, AIP was identified through its interaction with and transcriptional suppression
of  the  hepatitis  B  virus  (HBV)  X  protein;  HBV X protein  is  possibly  required  for  the  viral
replication in vivo, and may play a role in HBV-induced carcinogenesis (Petrulis & Perdew,
2002). Hence, AIP is also known as HBV X-associated protein 2 (XAP2) (Kuzhandaivelu et
al., 1996). Carver & Bradfield (1997) independently identified AIP, to which they attributed
the name Aryl Hydrocarbon Receptor (AHR)-associated protein 9 (hence ‘ARA9’).
 AHR,  also  known  as  dioxin  receptor,  is  a  ligand-inducible  transcription  factor  that  plays
central role in regulating the cellular response to polycyclic aromatic compounds, such as
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (Meyer et al., 1998); AHR induces the
transcription of the xenobiotic metabolizing enzymes, such as cytochrome P450. In 1996, in a
yeast two-hybrid experiment aiming to identify novel interaction partners to AHR, AHR-
interacting protein (hence ‘AIP’) emerged as a previously unknown AHR partner in mouse
hepatoma cells (Ma & Whitlock, 1997).
Ma & Whitlock (1997) found that the mouse Aip cDNA contained an open reading frame
that coded for a protein of 330 aa, with a molecular mass of ~37 kDa. A region of mouse Aip
exhibits sequence homology with human and mouse immunophilin FKBP proteins, which
are molecular chaperones involved in steroid receptor signalling and nuclear targeting,
protein folding, heat shock responses, and drug-induced immunosuppression (reviewed in
Ma & Whitlock, 1997). In addition, AIP harbors three tetratricopeptide repeats (TPRs), a 34
aa motif mediating various protein-protein interactions (Lamb et al., 1995), one of which is
the interaction with AHR (Fig. 7). TPR motifs have been identified in a diverse group of
proteins involved in mitosis, protein import, RNA splicing, neurogenesis, transcription, and
serine/threonine phosphorylation, and are essential for the assembly of multi-protein
complexes (Goebl & Yanagida, 1991; Lamb et al., 1995).
In uninduced cells, AIP exists in a cytoplasmic complex with AHR and HSP90, the latter
required for the proper folding of AHR (Carver et al., 1998; Petrulis & Perdew, 2002). The
presence of ligands, such as dioxin and dioxin-like chemicals, results in the dissociation of
the complex and the translocation of AHR into the nucleus, where it forms a heterodimer
transcription complex with AHR nuclear translocator (ARNT). The AHR/ARNT complex
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mediates the xenobiotic metabolizing response, by binding to specific DNA elements,
known as dioxin responsive elements (DREs) and initiating transcription of detoxification
enzymes (Fig. 8). AIP- AHR and AIP-HSP90 interactions are mediated through the AIP TPR
domains (Carver et al., 1998). Bell & Poland (2000) also showed that the last five amino acids
of the protein are of crucial importance for its interaction with AHR (Fig. 7).
Figure 7. Schematic representation
of  the  AIP  protein  with  its  FKBP
and TPR domains (adapted from
van der Spuy, 2006). The vertical
dashed line indicates  the last  5  aa
that are crucial for the interaction
of AIP with AHR.
Overall, it is now known that AIP maintains the cytoplasmic localization of AHR, via its
association with HSP90, thus preventing the nuclear accumulation of the ligand-activated
receptor. In addition, AIP increases the ligand binding capacity of AHR, alters the ability of
AHR to be recognized by importin ? (Fig. 8), and decreases the receptor’s proteosomal
degradation by protecting it against ubiquitination (Kazlauskas et al., 2000; Petrulis &
Perdew, 2002; Pollenz & Dougherty, 2005).
Figure 8. A simplified model of the human cytoplasmic AHR multi-protein complex and its
translocation into the nucleus upon ligand binding (modified from Meyer & Perdew, 1999; Petrulis &
Perdew, 2002; Ramadoss et al., 2004). The AIP/AHR/HSP90 complex can translocate into the nucleus
irrespectively of the ligand-bound or ligand-free state of AHR.
In general, the interaction of AIP with AHR and HSP90 appears to be conserved across
mammalian species (Meyer et al., 1998; Meyer & Perdew, 1999; Bell & Poland, 2000); yet,
some differences have been observed between the mouse and human AIP/AHR interaction:
Mouse Aip increases the cytoplasmic levels of Ahr by inhibiting its nucleocytoplasmic
shuttling and its binding to importin ?, whereas human AIP does not hinder the latter
interaction; as a result human AIP seems to translocate into the nucleus with the AHR
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complex, either in the presence or absence of ligand (Fig. 8). In contrast, mouse Aip seems to
dissociate from Ahr prior to its nuclear translocation (Ramadoss et al., 2004). The biological
effect of these differences is not known, but some caution is needed when extrapolating
results from the murine model to humans.
6.2 Possible implications of AIP/AHR pathway in AIP-mediated tumorigenesis
Until recently, environmental factors had not been rigorously implicated in pituitary
tumorigenesis (DeLellis et al., 2004); however, since AIP is part of the AHR-mediated
xenobiotic metabolic pathway, the role of dioxin and dioxin-like chemicals warrants further
investigation. Prolonged exposure of cells to chemical carcinogens can render them
vulnerable to tumorigenesis (Weinberg, 2007). To date, definitive correlation between dioxin
exposure and pituitary adenoma development is lacking. Yet, Pesatori et al. (2008) recently
analyzed the occurence of pituitary adenomas in the Seveso population (Italy), after a dioxin
exposure accident in 1976; despite the lack of statistically significant increase in the
prevalence of pituitary adenomas, a tendency toward a higher risk of pituitary
tumorigenesis was observed in subjects that had been exposed to high or intermediate
dioxin concentrations compared to low-exposed and non-contaminated reference
population. Similar detailed analyses may be a laborious task with human subjects, yet,
animal models of PAP, such as Aip+/- mice, may facilitate testing this hypothesis in a more
controllable fashion. If this is the correct pathway, it remains unknown why AIP-mediated
chemical-induced tumorigenesis seems to exclusively affect the anterior pituitary tissue,
despite the ubiquitous expression of AIP and AHR in all human tissues.
Some clues in AIP-associated tumorigenesis may lie in the interaction of AHR with cell cycle
regulators,  such  as  p27Kip1 and  pRB.  AHR  was  shown  to  inhibit  cell  cycle  progression  in
dioxin-induced rat hepatoma cells, by directly and specifically inducing the cell cycle
inhibitor p27Kip1. This induction occurs at the mRNA expression level and not on p27Kip1
protein stability or the rate of p27Kip1 mRNA translation (Kolluri et al., 1999). In pituitary
adenomas, p27Kip1 protein expression levels are significantly reduced (Table 6) (Takeuchi et
al., 1998; Dahia et al., 1998; Lidhar et al., 1999; Bamberger et al., 1999), thus neoplastic
pituitary cells appear to have lost a crucial cell proliferation brake.
Another mechanism by which AHR seems to exert anti-proliferative activity, upon dioxin
induction of rat hepatoma cells, is through the direct interaction with the retinoblastoma
protein pRB. pRB is a negative regulator of the cell cycle G1/S phase transition via the direct
binding and inhibition of E2F transcription factors (Ge & Elferink, 1998; Puga et al., 2000).
Puga et al. (2000) demonstrated that, under the presence of mitogenic signals, AHR directly
binds pRB and cooperates to the repression of E2F-dependent transcription of target genes
that lead to G1/S phase transition. Moreover, Marlowe et al. (2008) showed that ligand-
induced AHR activation leads to direct formation of nuclear AHR-E2F1 complexes, resulting
in  inhibition  of  E2F1-dependent  expression  of  proapoptotic  genes  and,  thus,  inhibition  of
apoptosis. Thus, it seems that AHR, pRB, and E2Fs may synergistically activate an
environmental checkpoint that regulates the balance between cell cycle progression and
arrest. It may be that loss of AIP is linked to these pathways, by perturbing the role of AHR
and compromising the delicate cellular balance. Aggressive pituitary adenomas and
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carcinomas appear to have lost the PRB chromosomal locus or the gene is rendered silent
due to promoter hypermethylation (Table 6) (Boikos & Stratakis, 2007).
6.3 Other AIP interaction partners and possible implications in AIP-mediated
tumorigenesis
Aip is ubiquitously expressed during mouse embryonic development, as early as E9.5,
preceding expression of other Aip-associated proteins, such as Ahr (Abbott et al., 1995); this
suggests that Aip functions in other signal transduction pathways apart from the Ahr
pathway (Carver et al., 1998; Lin et al., 2007).
Indeed, AIP has been reported to bind a number of other proteins, such as the Epstein-Barr
virus nuclear antigen 3 (EBNA-3), a transcriptional transactivator with an unclear functional
role in viral pathogenesis (Krauer et al., 1996; Kashuba et al., 2000). Later, AIP was found to
interact via its TPR domains with the TPR motif present in the C-terminal domain of Tom20,
a  main  mitochondrial  import  receptor.  AIP  bound  specifically  also  to  mitochondrial
preproteins, maintained their unfolded status and suppressed their aggregation in the
cytoplasm; thus, AIP exhibits a chaperone-like activity (Yano et al., 2003). At the same time,
it was demonstrated that AIP interacts with a nuclear receptor of the steroid receptor
superfamily, the peroxisome proliferator-activated receptor ? (PPAR?), in a complex with
HSP90 (Sumanasekera et al., 2003). In humans, PPAR? regulates energy homeostasis via
control of lipid metabolism. Sumanasekera et al. (2003) showed that AIP represses the
transcriptional activity of PPAR?, but this interaction has not been addressed in the
pituitary tissue.
Kang & Altieri (2006) demonstrated the role of AIP in the stabilization of survivin, an
inhibitor of apoptosis and regulator of cell division, a pathway that could be theoretically
associated with the possible progression of adenomas to more aggressive tumors (Altieri,
2003; Kang & Altieri, 2006). Survivin, which is present during fetal development, but
undetectable in terminally differentiated normal adult tissues, is overexpressed in many
human tumors, including pituitary adenomas (Wasko et al., 2005; Hassounah et al., 2005),
and this interaction warrants further investigation. Recently, AIP was also shown to
specifically interact with TR?1, one of the two nuclear thyroid hormone receptors (TR?1 and
TR?2) that upon T3 thyroid hormone binding, they modulate the hypothalamic TRH
transcription (Froidevaux et al., 2006). Interestingly, this group demonstrated that AIP is
necessary for a T3-independent TR?1-mediated TRH transcription.
Moreover, AIP specifically interacts with cAMP-specific phosphodiesterase PDE4A5 and
directly inhibits its enzymatic activity and attenuates the ability of PDE4A5 to be
phosphorylated by the cAMP-dependent PKA (Bolger et al., 2003). Functional validation of
the effect of five germline AIP mutations detected in pituitary adenoma patients, including
two missense (C238Y, R271W) and three nonsense (R81X, Q217X, R304X) mutations,
revealed that all changes abolish the interaction of AIP with PDE4A5. Because the same
observation was made for three different cell lines, including the rat mixed GH/PRL-
secreting adenoma cell line (GH3), a human embryonic kidney cell line (HEK293), and a
human embryonic lung fibroblast cell line (TIG3), these results pose additional questions
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regarding the tumorigenic effects of AIP loss in the human pituitary specifically (Leontiou et
al., 2008).
Interestingly, human AIP functionally interacts with a different phosphodiesterase isotype,
PDE2A, involved in the hydrolysis of cAMP (de Oliveira et al., 2007). It had been shown
earlier that elevation of cAMP levels induces the nuclear translocation of AHR, in the
absence of exogenous ligands; cAMP-induced AHR adopts a structure that hinders
interaction with ARNT and, thus, acting as a repressor rather than an activator of AHR-
dependent gene expression (Oesch-Bartlomowicz et al., 2005). Later, de Oliveira et al. (2007)
provided further evidence that PDE2A mediates the cytosolic sequestration of AHR,
presumably via locally reducing the cAMP levels. It may be that in the absence of functional
AIP, PDE2A promotes increase in cAMP levels, and nuclear translocation of cAMP-induced
AHR, which in turn orchestrates a different gene expression pattern compared to the one
activated by dioxin-induced AHR/ARNT complexes. Whether these facts create a permissive
environment for pituitary tumorigenesis deserves further investigation.
It is of great interest that genes involved in cAMP-dependent signalling have been
previously found causative for tumorigenesis in endocrine tissues: GNAS, which codes for
Gs?, harbors somatic mutations in as many as 40% of sporadic GH-secreting adenomas and
germline mutations in MAS patients with GH-secreting adenomas. Gs? is  required  for  the
activation of adenylyl cyclase, which in turn increases cAMP levels, leading to a signalling
cascade through the activation of protein kinases in many cell types, including pituitary cells
(see Introduction, section 3.1.1). Moreover, PRKAR1A carries inactivating mutations in the
majority of CNC patients (see Introduction, section 3.2.2). In this case, unconstrained
phosphorylation of cAMP by PKA, results in elevated mitogenic signalling, as explained
above. In addition, inactivating germline mutations in the PDE11A gene predispose to
micronodular adrenocortical hyperplasia in a subgroup of patients with Cushing’s
syndrome. PDE11A also catalyzes cAMP and cGMP, and cAMP levels are found increased
in PDE11A mutation-positive adrenal tissue samples compared to controls (Horvath et al.,
2006). It was later shown that less severe germline PDE11A mutations predispose to a
variety of benign and malignant adrenocortical tumor types; these PDE11A variants may
account for the genetic predisposition of adrenocortical tumors on population level (Libe et
al., 2008). Lastly, PDE8B has been also found mutated or underexpressed in adrenocortical
hyperplasia (Horvath et al., 2008). However, possible interactions of PDE11A and PDE8B
with AHR or AIP have not been reported yet. In the anterior pituitary gland tissue,
deregulated cAMP signalling may act as the initiating event for hyperplasia and/or
adenoma development. Additional events leading to cell cycle disregulation and genomic
instability  could  allow  for  the  monoclonal  expansion  of  a  pituitary  tumor  (Boikos  &
Stratakis, 2007).
Overall, AIP directly associates with a number of interaction partners (Table 10) and all
these interactions are mediated by its C-terminal TPR motifs. In general, AIP acts as a
molecular chaperone, whereas it represses the transcriptional activity of the transcription
factors it binds. Despite the variety of these interactions, little can be told currently
regarding the mechanisms by which AIP leads to pituitary tumorigenesis; further studies
are needed to address its role in normal pituitary cells, before conclusions can be drawn for
its implications in the adenomatous pituitary.
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Only recently has the expression pattern of AIP been somewhat elucidated in the normal
versus the adenomatous pituitary tissue: In the normal pituitary, AIP co-localizes only with
GH and PRL in the secretory vesicles of GH and PRL producing cells, but ACTH, TSH, and
FSH/LH  producing  cells  do  not  express  AIP  (Leontiou et al., 2008). However, in sporadic
pituitary adenomas, AIP is expressed in all adenoma types studied (GH-, PRL-, ACTH-
secreting, and FSH-positive NFPAs), but remains co-localized only with GH in the secretory
vesicles of the GH-secreting adenomas, as in the normal pituitary; contrary, AIP remains in
the cytoplasm of PRL- and ACTH-secreting adenomas, and NFPAs (Leontiou et al., 2008). To
date, the mechanisms that induce the expression of AIP in non-GH and non-PRL-secreting
adenomas remain unknown.
Table 10. AIP partners and the functions mediated through these interactions.
AIP interaction
partners
AIP Function Reference
HBV X protein Suppression of the transcriptional activity of HBV X protein Kuzhandaivelu et al., 1996
AHR – HSP90 ? Cytoplasmic stabilization of AHR
? Prevention of the nucleocytoplasmic shuttling of AHR
? Increase of AHR ligand binding capacity
? Increase of recognition of AHR by importin ?
? Protection of AHR from ubiquitination and targeting for
proteosomal degradation
Ma & Whitlock, 1997;
Carver & Bradfield, 1997;
Carver et al., 1998
EBNA3 Undefined role Kashuba et al., 2000
Tom20 and
mitochondrial
preproteins
Chaperone-like activity for the maintenance of unfolded
and non-aggregated mitochondrial preproteins in the
cytoplasm
Yano et al., 2003
PPAR? – HSP90   Repression of PPAR?-mediated transcription Sumanasekera et al., 2003
PDE4A5 Attenutation of the activity of PDE4A5 and its ability to be
phosphorylated by PKA
Bolger et al., 2003
Survivin Regulation of surviving stability Kang & Altieri, 2006
TR?1 T3-independent TR?1-mediated TRH transcription Froidevaux et al., 2006
PDE2A Targeting of PDE2A to the AHR complex and restriction of
AHR nucleo-cytoplasmic motility
de Oliveira et al., 2007
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CONCLUSIONS AND FUTURE PROSPECTS
The recent studies addressing the prevalence of clinically relevant pituitary adenomas
indicate that these tumors occur more often than previously thought (Daly et al., 2006a; Daly
et al., 2007a). Thus, the need to comprehend the mechanisms underlying this type of
tumorigenesis is important, in order to provide improved diagnosis and treatment. The
contribution of genetics towards this end has been the localization and identification of four,
so far, endocrine-related tumor predisposing genes, namely MEN1, PRKAR1A, CDKN1B,
and AIP, in MEN1, CNC, MEN1-like (MEN4), and PAP, respectively.
This work describes the methodological  approach that led to the elucidation of  the genetic
component underlying a form of pituitary adenoma predisposition (PAP) with incomplete
penetrance, caused by dominantly inherited germline mutations in AIP (I). The conclusions
drawn from this and the subsequent studies are summarized as follows:
I) The Finnish founder AIP mutation, Q14X, was originally identified in two affected
families from Northern Finland, with multiple cases of pituitary adenomas of the GH/PRL-
secreting cell lineage. Q14X was also detected among sporadic Finnish acromegaly patients:
Two AIP mutations, Q14X and IVS3-1G>A, account for 16% of the Nordic population-based
cohort, and for 40% of these patients diagnosed before the age of 35 years. Genetic data
presented herein – i.e. inactivating germline mutations segregating among the affected
individuals, and biallelic inactivation of AIP in the studied tumors – provide support to the
notion that AIP is likely to act as a tumor suppressor gene.
II) Germline AIP mutations are found in populations of various ethnic origins; the mutation
prevalence is low (0.8-7.4%), varying in different clinical settings. Overall, it emerges that
AIP mutations are enriched among patients with very young age at onset and/or a positive
family history of acromegaly. These patients are diagnosed mainly with GH-secreting
adenomas (II). AIP IHC was tested as a pre-screening molecular tool and was found to be a
useful predictor of PAP, with 75% sensitivity and 95% specificity for germline truncating
AIP mutations. Further investigation is required before its clinical application, since little is
known concerning normal and aberrant AIP localization in normal and adenomatous
pituitaries, respectively.
III)  The  study  of  common  tumor  types,  including  a  large  collection  of  MSI  and  MSS
colorectal, breast, and prostate tumors, did not reveal somatic mutations in AIP, suggesting
that this gene is not involved in such tumorigenesis.
IV) The screening of pediatric pituitary adenoma patients revealed that AIP mutations once
again underlie the early onset of GH-secreting adenomas, without an evident family history,
but seem to be very rare in non-GH-secreting pediatric tumors. This finding has
implications regarding genetic testing of very young acromegaly/gigantism patients and
their families.
The lack of AIP mutations in a large number of familial pituitary adenoma cases analyzed
worldwide to date, implies that other susceptibility genes await identification, a fact that
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will expand the spectrum of genetic heterogeneity in familial pituitary adenomas. On the
other hand, in sporadic patients without identified intragenic AIP mutations, it is
theoretically possible that other mechanisms result in AIP inactivation; methylation of genes
in pituitary adenomas is not an infrequent event (reviewed in Farrell et al., 1999; Farrell &
Clayton, 2003). Epigenetic silencing through promoter hypermethylation is a mechanism
estimated to be involved in the inactivation of more than 50% of TSG in sporadic tumors of
various types (Baylin & Herman, 2000); it remains to be shown whether this applies to AIP.
One important question that remains to be answered, which may have direct implications in
disease outcome and counseling, is the functional validation of the mutations that do not
cause transcript degradation. This is a question that could be addressed either by classical
cell-based studies or by the more laborious generation of genetically engineered animal
models. For instance, hypomorphic Aip mice, with reduced Aip expression in the germline,
exhibit hepatovascular defects and reduced liver weights, but implications caused by the
hypomorphic allele in the pituitary were not reported (Lin et al., 2008). Overall, it will be
challenging to robustly evaluate the effect of missense, small in-frame insertions and
deletions, or in-frame whole-exon deletions in human pituitary tumor predisposition.
An issue of clinical relevance is whether AIP mutations have an impact on the patients’
response to currently available therapy (Beckers and Daly, 2007; Daly et al., 2007a).
Preliminary results show that AIP mutation-positive tumors are large and often invasive;
therapeutic response is often poor, with infrequent surgical cure, significant resistance to
somatostatin analogs, and frequent radiotherapy (Daly et al., 2008). Further work on the
functional role of AIP will hopefully reveal novel cellular mechanisms of pituitary
tumorigenesis, including potential drug targets. Other issues of clinical relevance to be
addressed in the future will be the study of the phenotypic variation(s) in PAP, the possible
existence of genotype-phenotype correlations, as well as the estimation of the disease
penetrance. These issues will have direct implications in genetic counseling; yet, the overall
benefits of predictive genetic testing should be assessed.
Despite the limitations, such as lack of functional human cell lines, appropriate animal
models, and the critical location of the pituitary gland, significant progress has been made in
understanding the genetic and molecular basis of pituitary tumorigenesis. Rodent pituitary
cell lines are of course available, but it is not certain that they faithfully depict the human
pituitary gene expression profile and biology. Among the primary future prospects of this
project would be the elucidation of the role of AIP in pituitary tumorigenesis. One means of
doing so will undoubtedly be the development of appropriate animal models. A knock-out
mouse model has already been engineered (Lin et al., 2007). Despite the lack of viability,
constitutional knockout mouse models could provide the material for the development of
cellular models, such as embryonic fibroblast Aip knockout  cell  lines,  in  order  to  further
experiment on. A conditional mouse model (i.e. pituitary-specific), similar to the pituitary
and pancreas-specific Men1 knockout model (Biondi et al., 2004) or the pituitary-specific
Prkar1a knockout model (Yin et al., 2008), will hopefully facilitate future studies addressing
the role of AIP in pituitary tumorigenesis.
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Figure 1. The  distribution  of  different  types  of  germline AIP mutations identified in familial and
sporadic  pituitary  adenoma  patients  of  European,  American,  and  Asian  origin,  as  reported  in  the
literature between May 2006 and June 2008.
Table 1. Germline AIP mutations identified in pituitary adenoma patients of European, American, and Asian origin, as reported in the
literature between May 2006 and June 2008.
Mutation
(Protein level)
Mutation
(Transcript level)
AIP Fragment Patient origin* Pituitary adenoma phenotype of AIP
mutation-positive patients
Tumor analysis
(second hit
mutation)
Family
history
Reference
Familial
Nonsense
Q14X c.40C>T Exon 1 Finland (11 cases)
Finland (2 cases)
GH- (4), GH/PRL- (2), PRL-secreting (3)
GH-secreting (2)
LOH
LOH
study I
study I
E24X c.70G>T Exon 1 Brazil (7 cases) GH- (6), GH/PRL-secreting (1) LOH Leontiou et al., 2008
R81X c.241C>T Exon 2 USA (2 cases)
Brazil (2 cases)
GH/PRL-secreting (2)
GH-secreting (2)
LOH
LOH
Leontiou et al., 2008
Toledo et al., 2008
Q142X c.424C>T Exon 3 Italy (4 cases) GH- (3), PRL-secreting (1) NA Daly et al., 2007b
Q217X c.649C>T Exon 5 Belgium (2 cases) GH- (1), GH/PRL-secreting (1) NA Daly et al., 2007b
Q239X c.715C>T Exon 5 France (2 cases) GH-secreting (2) NA Daly et al., 2007b
Y268X c.804A>C Exon 6 Brazil (3 cases) GH-secreting (2), NFPA** (1) NA Toledo et al., 2007
R304X c.910C>T Exon 6 Italy (2 cases)
Italy (3 cases)
Romania (2 cases)
UK (8 cases)
GH-secreting (2)
GH- (2), GH/PRL-secreting (1)
NA (? serum GH and PRL) (2)
GH- (6), PRL- (1), GH/PRL-secreting (1)
NA
NA
NA
NA
study I
Daly et al., 2007b
Leontiou et al., 2008
Leontiou et al., 2008
Frameshift
P96fs c.286-287delGT Exon 3 Japan (3 cases) GH- (2), GH/PRL-secreting (1) LOH Iwata et al., 2007
E174fs c.517-521delGAAGA Exon 4 Brazil (3 cases) GH- (2), GH/PRL-secreting (1) NA
LOH equivocal
Daly et al., 2007b and
Naves et al., 2007
L181fs c.542delT Exon 4 Spain (1 case) GH-secreting NA Acromegaly study II
Q285fs c.854-857delAGGC Exon 6 Italy (2 cases) GH- (1), GH/PRL-secreting (1) NA Daly et al., 2007b
Q307fs c.919insC Exon 6 NA (1 case) GH-secreting NA Prolactinoma Beckers et al., 2008
In-frame deletions
G23_E24 c.66-71delAGGAGA Exon 1 Germany (1 case) GH-secreting LOH Acromegaly study II
G47_R54 c.138-161del24 Exon 2 Argentina (2 cases) GH-secreting (2) NA Daly et al., 2007b
In-frame insertions
A274_H275ins10 c.794-823dup30 Exon 6 UK (3 cases) GH-secreting (3) LOH Leontiou et al., 2008
Large genomic deletions
A34_K93 Ex2del (?1562bp) Exon 2 UK (2 cases) NFPA (1), GH-secreting (1) NA NFPA Georgitsi et al., 2008
na Ex1_2del (?5818kb) Exons 1-2 Germany (2 cases) GH-secreting (2) NA Georgitsi et al., 2008
Missense
C238Y c.713G>A Exon 5 Mexico (3 cases) GH-secreting (3) LOH Leontiou et al., 2008
K241E c.721A>G Exon 5 Belgium (2 cases) PRL-secreting (1), NFPA (?LH/SU+) (1) NA Daly et al., 2007b
R271W Exon 6 France (2 cases)
France (2 cases)
GH-secreting (2)
GH- (1), PRL-secreting (1)
NA
NA
Daly et al., 2007b
Daly et al., 2007b
R304Q c.911G>A Exon 6 Romania (2 cases)
Italy (1 case)
Canada (2 cases)
GH-secreting (2)
GH-secreting
GH-secreting (1)
NA
NA
NA
Prolactinoma
Leontiou et al., 2008
Unpublished data
Vallette et al., (ENDO2007,
oral communication)
Promoter
na na
(c.-270-269CG>AA and
c.-220G>A)
na Japan (2 cases) GH- (1), GH/PRL-secreting (1) LOH Leontiou et al., 2008
Sporadic
Nonsense
Q14X c.40C>T Exon 1 Finland (4 cases)
Finland (2 cases)
Finland (2 cases)
GH- (3), GH/PRL-secreting (1)
GH-secreting (2)
GH/PRL- (1), PRL-secreting (1)
LOH
LOH
LOH
study I
study II
Raitila et al., 2006
R22X c. 64C>T Exon 1 France GH-secreting LOH Barlier et al., 2007
K201X c. 601A>T Exon 4 France (2 cases) GH-secreting (2) NA Cazabat et al., 2007
K241X c.721A>T Exon 5 NA PRL-secreting NA Beckers et al., 2008
R304X c.910C>T Exon 6 France GH-secreting NA Cazabat et al., 2007
Frameshift
P114fs NA Exon 3 NA GH-secreting NA Beckers et al., 2008
H135Lfs c.404delA Exon 3 France GH-secreting NA Cazabat et al., 2007
H275Qfs c.824-825insA Exon 6 USA GH-secreting LOH study II
In-frame deletions
Y248del c.742-744delTAC Exon 5 Italy GH-secreting LOH study IV
L294_A297del c.880-891del12 Exon 6 Germany GH-secreting LOH study II
Splice-site bp substitution
na IVS2-1G>C IVS2-Exon 3 USA GH-secreting NA study II
na IVS3-1G>A IVS3-Exon 4 Finland GH/PRL-secreting LOH equivocal study I
na IVS3-2A>G IVS3-Exon 4 France GH/PRL-secreting NA Cazabat et al., 2007
Missense
K103R NA Exon 3 NA ACTH-secreting (Cushing’s disease) NA Beckers et al., 2008
A299V c.896C>T Exon 6 The Netherlands GH-secreting NA study II
E293G c.878-879AG>GT Exon 6 Germany GH-secreting LOH study II
R304Q c.911G>A Exon 6 Poland
France
ACTH-secreting (Cushing’s disease)
GH-secreting
NA
NA
study II
Cazabat et al., 2007
NA, information not available; IVS, intron variable sequence (i.e. intron); na, not applicable
* In sporadic cases only one case with each mutation was identified, unless otherwise stated in parenthesis.
** Pituitary nodule, likely a NFPA microadenoma (3 mm)
